Targeted dephosphorylation of tau
Patent Information
- Application Number
- PCT/US2024/017910
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-01
- Filing Date
- 2024-02-29
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for tauopathies, such as Alzheimer's disease and frontotemporal dementia, lack effective options to address the progressive degeneration and toxicity associated with Tau protein accumulation, leading to debilitating and often fatal neurodegenerative disorders.
Development of bifunctional small molecules that bind to Tau protein, recruit PP2A phosphatase, and trigger dephosphorylation, reducing phosphorylated Tau levels and associated toxicity through targeted dephosphorylation and clearance in neuronal models.
The small molecules effectively reduce Tau species levels and oxidative stress, offering a potential therapeutic approach to delay or inhibit the onset of tauopathies by selectively targeting and clearing pathological Tau aggregates.
Smart Images

Figure US2024017910_21112024_PF_FP_ABST
Abstract
Description
TARGETED DEPHOSPHORYLATION OF TAU CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 449,161 filed March 1, 2023, which is hereby incorporated by reference, in its entirety for any and all purposes. TECHNICAL FIELD
[0002] The present technology relates generally to compositions and methods for treating, preventing, ameliorating, inhibiting and / or delaying the onset of tauopathies. Tauopathies are neurodegenerative disorders associated with the presence of abnormal Tau protein in the brain that cause the intra-cellular formation of Tau aggregates, filaments and tangles. Generally, the present technology relates to bifunctional small molecules having a Tau binder, a linker, and a PP2A binder or activator, or a pharmaceutically acceptable salt, hydrate, and / or solvate thereof, and methods of use thereof to treat a subject suffering from a tauopathy. BACKGROUND OF THE DISCLOSURE
[0003] The following description is provided to assist the understanding of the reader. None of the information provided or references cited is admitted to be prior art to the compositions and methods disclosed herein.
[0004] Tauopathies are a class of neurodegenerative diseases that affect a body’s activities such as balance, movement, talking, breathing and / or heart function. Tauopathies are generally incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. As the disease state progresses it can often lead to death of the afflicted subject. Some examples of tauopathies include: Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism–dementia complex, anti-IgLON5- related tauopathy, Caribbean Parkinsonism, chronic traumatic encephalopathy, diffuse neurofibrillary tangles with calcification, progressive supranuclear palsy, Down syndrome, Familial British dementia, Familial Danish dementia, Niemann-Pick disease type C, non- Guamanian motor neuron disease with neurofibrillary tangles, postencephalitic Parkinsonism, primary age-related tauopathy, progressive ataxia, palatal tremor, neurofibrillary dementia, familial frontotemporal dementia, Parkinsonism, Pick's disease, argyrophilic grain disease, corticobasal degeneration, Guadeloupean Parkinsonism, globular glial tauopathy,Huntington's Disease, SLC9a-related Parkinsonism, argyrophilic grain disease, and primary age-related tauopathy, which includes neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy. Clinical symptoms include disinhibition, apathy, loss of empathy, stereotypic behaviors, hyperorality, memory loss, difficulty communicating and reasoning, confusion, loss of coordination, depression, anxiety, paranoia, agitation, hallucinations, postural instability, vertical supranuclear ophthalmoplegia, asymmetrical limb apraxia, cortical function deficits, asymmetric onset of tremor, bradykinesia, rigidity, cerebellar ataxia, difficulty speaking, anomia, impaired comprehension, phonemic paraphasia, motor speech disorder, visuospatial disorientation, impaired executive abilities, or any combination thereof. There is currently a strong need for drugs suitable for treating subjects suffering from, or based on genetic, lifestyle or environmental considerations are expected to suffer from, tauopathies related to a disease state. SUMMARY
[0005] In one aspect, the present disclosure provides a compound of Formula I, II, III, or IV:Ar1is a group of FormulaR1is H or alkyl; R2is H or alkyl; R3-R8are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R4and R5or R7and R8may join together to form a fused ring; L1is a linking group that is alkylene or a group of Formula AFormula A indicates the end that binds to Ar1; R34-R37are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R34and R35or R36and R37may join together to form a fused ring; L2is a linking group that is a group of Formula B, C, D, or E:where Ar2in Formula B, C, and D indicates the end that binds to Ar2; R30, R31, R38, R39, and R40are individually alkylenyl groups, polyethylene glycol groups, or polypropylene glycol groups; R32, R33, and R50are individually H or alkyl; R41-R44are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R41and R42or R43and R44may join together to form a fused ring;Ar2is a group of FormulaAr3is a group of FormulaR9is -CH2-, -CH2CH2-, -S-, or -O-; R10-R17are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R9-R16may join together to form a fused ring; L3is an alkylenyl group; R51-R57are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R51-R57may join together to form a fused ring; and R58is H, a group of formula -CH2NR59C(O)R60NR61Pr, or a group of formula -CH2NR59C(O)R60NR61Pr; R59and R61are individually H or alkyl; R60is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; Pr is H, alkyl, an amine protecting group, a group of formula -C(O)R62Ar1, or a group of Formula E; R62is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; R70is H, -C(O)OH, or -C(O)N(R59)R60NR61Pr; and R71is H, F, Cl, Br, or I.
[0006] In some embodiments, the compound is of Formula I and each of R1and R32is individually H, methyl, or ethyl; each of R2-R8, R10-R15, R17, and R34-R37is H; and R16is F,Cl, or Br. In some embodiments, the compound is of Formula I and L1is methylene, ethylene, propylene, or butylene. In some embodiments, the compound is of Formula I and L1is a group of Formula A. In some embodiments, the compound is of Formula I and R31is methylene, ethylene, propylene, or butylene; and R30is C4-C10alkylene, -(CH2CH2O)n- CH2CH2-, wherein n is 1 to 10. In some embodiments, the compound is of Formula I and R9is -CH2CH2-. In some embodiments, the compound is of Formula I, L2is of Formula C, and R38is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10. In some embodiments, the compound is of Formula I, L2is of Formula B, and R30is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10. In some embodiments, the compound is of Formula I, L2is of Formula D, and R40is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and each of R41-R44is H. In some embodiments, the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or -(CH2CH2O)n- CH2CH2-; and Pr is H, methyl, a tert-butyloxycarbonyl (boc) group, or a group of formula - C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H. In some embodiments, the compound is of Formula I, L2is of Formula B, R31is methylene, ethylene, propylene, or butylene; and R30is -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, R9is -CH2CH2-, and R16is Cl. In some embodiments, the compound is of Formula I, L2is of Formula C, R38is -C4-C10alkylenyl-, -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, and R39is methylene, ethylene, propylene, or butylene. In some embodiments, the compound is of Formula I, L1is methylene, ethylene, propylene, or butylene; R40is -C4- C10alkylenyl-, -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10. In some embodiments, the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or -(CH2CH2O)n-CH2CH2- and n is 1 to 10; and Pr is a group of formula - C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H. In some embodiments, the compound is of Formula III; R71is Cl, R70is - C(O)N(R59)R60NR61Pr, R59is H or methyl, R60is C4-C10alkylene or -(CH2CH2O)n-CH2CH2and n is 1 to 10, R61is H or methyl, and Pr is the group of formula -C(O)R62Ar1. In some embodiments, the compound is any one or more of:.
[0007] In one aspect the present disclosure provides a composition comprising, consisting essentially of, or consisting of, the compound of any one of the preceding embodiments or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof and a pharmaceutically acceptable carrier.
[0008] In one aspect the present disclosure provides a composition comprising, consisting essentially of, or consisting of, the compound of certain preceding embodiments, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof and a pharmaceutically acceptable carrier. In some embodiments, the composition of any of the preceding embodiments further comprises at least one additional therapeutic agent.
[0009] In one aspect the present disclosure provides a method for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, the method comprising, consisting essentially of, or consisting of, administering to the subject a composition comprising a therapeutically effective amount of the compound of any one of the preceding embodiments, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof, or the composition of any one of the preceding embodiments. In some embodiments, the method comprises, consists essentially of, or consists of, administering to the subject a therapeutically effective amount of the compound of certain preceding embodiments, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, administration of the compound or composition reduces Tau species levels and / or reduces the toxicity associated with cellular Tau accumulation. In some embodiments, administration of the compound or composition reduces cellular oxidative stress caused by cellular accumulation of Tau protein. In some embodiments, the subject has been diagnosed as having Alzheimer’s disease, frontotemporal dementia, Pick’s disease, corticobasal degeneration, progressive supranuclear palsyglobal glial tauopathy, argyrophilic grain disease, familial British dementia or familial Danish dementia. In some embodiments, the subject has been diagnosed as having a primary age-related tauopathy. In some embodiments, the primary age-related tauopathy is selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy. In some embodiments, the compound or composition is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 2 weeks or more. In some embodiments, the compound or composition is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 12 weeks or more, 24 weeks or more, 48 weeks or more, 1 year or more, 2 years or more, or 5 years or more. In some embodiments, the compound or composition is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the compound or composition is no longer effective. In some embodiments, the subject is a mammal. In some embodiments, the mammalian subject is a human. In some embodiments, the compound or composition is administered orally. In some embodiments, the compound or composition is administered subcutaneously. In some embodiments, the compound or composition is administered topically, intranasally, systemically, intravenously, intraperitoneally, intradermally,intraocularly, ophthalmically, intrathecally, intracerebroventricularly, iontophoretically, transmucosally, intravitreally, or intramuscularly.
[0010] In one aspect the present disclosure provides a method for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, the method comprising, consisting essentially of, or consisting of, administering to the subject a composition comprising, consisting essentially of, or consisting of, a therapeutically effective amount of the compound of any one of certain preceding embodiments, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient. In any of the preceding embodiments, the method further comprises, consists essentially of, or consists, administering at least one additional therapeutic agent.
[0011] In one aspect the present disclosure provides use of a composition in the preparation of a medicament for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition comprises, consists essentially of, or consists of, the compound or any one of the preceding embodiments or the composition of any one of the preceding embodiments. In some embodiments, the composition comprises the compound of certain preceding embodiments, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, use of the composition reduces Tau species levels and / or reduces the toxicity associated with cellular Tau accumulation. In some embodiments, use of the composition reduces cellular oxidative stress caused by cellular accumulation of Tau protein. In some embodiments, the subject has been diagnosed as having Alzheimer’s disease, Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, global glial tauopathy, argyrophilic grain disease, familial British dementia or familial Danish dementia. In some embodiments, the subject has been diagnosed as having a primary age-related tauopathy. In some embodiments, the primary age-related tauopathy is selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging- related Tau astrogliopathy. In some embodiments, the composition / medicament is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 2 weeks or more. In some embodiments, the composition / medicament is administered at least once per day, at least once every 2 days, at least once every 3 days, atleast once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 12 weeks or more, 24 weeks or more, 48 weeks or more, 1 year or more, 2 years or more, or 5 years or more. In some embodiments, the composition / medicament is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the composition is no longer effective. In some embodiments, the subject is a mammal. In some embodiments, the mammalian subject is a human. In some embodiments, the composition / medicament is formulated for oral administration. In some embodiments, the composition / medicament is formulated for subcutaneous administration. In some embodiments, the composition / medicament is formulated for administration, topically, intranasally, systemically, intravenously, intraperitoneally, intradermally, intraocularly, ophthalmically, intrathecally, intracerebroventricularly, intracerebroventricularly, iontophoretically, transmucosally, intravitreally, or intramuscularly.
[0012] In one aspect the present disclosure provides use of a composition in the preparation of a medicament for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition comprises the compound of certain preceding embodiments. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient. In any of the preceding embodiments, the composition further comprises at least one additional therapeutic agent. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIGs. 1A-1C are a diagram showing the model mechanism of action for Tau phosphoeditors (FIG. 1A) and assessment thereof by inhibiting ternary complex formation with (FIG. 1B) excess Tau ligand T807, or (FIG. 1C) a phosphatase inhibitor (e.g., okadaic acid).
[0014] FIGs. 2A-2E are a series of western blots and densitometry quantifications showing the abundance of different forms of phosphorylated (S262, S202 / T205 or AT8) and total Tau (TAU5), and ratios thereof (normalized to internal control Actin and relative to vehicle- 0μM), in 6-week differentiated Tau-P301L patient derived neuronal cells treated with varying concentrations of the indicated small molecule for 24h.
[0015] FIGs. 3A-3E are a series of western blots and densitometry quantifications showing the abundance of different forms of phosphorylated (S262, S202 / T205 or AT8) and total Tau (TAU5), and ratios thereof (normalized to internal control Actin and relative to vehicle-0μM), in 6-week differentiated Tau-P301L patient derived neuronal cells treated with varying concentrations of the indicated small molecule for 24h.
[0016] FIGs. 4A-4F are a series of western blots and densitometry quantifications showing the abundance of different forms of phosphorylated (S262, S202 / T205 or AT8) and total Tau (TAU5), and ratios thereof (normalized to internal control Actin and relative to vehicle- 0μM), in 6-week differentiated Tau-P301L patient derived neuronal cells treated with varying concentrations of the indicated small molecule for 24h.
[0017] FIGs. 5A-5E are a series of western blots and densitometry quantifications showing the abundance of different forms of phosphorylated (S262, S202 / T205 or AT8) and total Tau (TAU5), and ratios thereof (normalized to internal control Actin and relative to vehicle- 0μM), in 6-week differentiated Tau-P301L patient derived neuronal cells treated with varying concentrations of the indicated small molecule for 24h.
[0018] FIGs. 6A-6E are a series of western blots and densitometry quantifications showing the abundance of different forms of phosphorylated (S262, S202 / T205 or AT8) and total Tau (TAU5), and ratios thereof (normalized to internal control Actin and relative to vehicle- 0μM), in 6-week differentiated Tau-P301L patient derived neuronal cells treated with varying concentrations of the indicated small molecule for 24h.
[0019] FIGs. 7A-7F show the results of western blots, and the densitometry quantification graphs thereof, of Tau-P301L patient derived neurons at 6 weeks of differentiation treated with varying concentrations of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01- 125, or JWJ-01-257 for 24h.
[0020] FIGs. 8A-8F show the results of western blots, and the densitometry quantification graphs thereof, of Tau-P301L patient derived neurons at 6 weeks of differentiation treated with varying concentrations of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01- 125, or JWJ-01-257 for 6h.
[0021] FIG. 9 is a series of western blot densitometry graphs showing the abundance of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262 (shown relative to control 0μM compound, i.e., vehicle alone; normalized to internal control Actin), and ratios to total Tau thereof, in Tau-P301L patient derived neurons at 6 weeks of differentiation treated withvarying concentrations of several control compounds, JWJ-1-065, FMF-06-124, and JWJ-1- 028 for 24h.
[0022] FIG. 10 is a series of graphs showing (top) the abundance of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262; as well as (bottom) pPP2A Y307, total PP2A, and ratios thereof, in Tau-P301L patient derived neurons at 6 weeks of differentiation treated with DMSO (vehicle control), T807 (a binder of misfolded Tau), the PP2A inhibitor okadaic acid (O.A.), the PP2A inhibitor LB100, or the PP2A inhibitor Fostriecin, for 24h. Relative levels were determined via densitometric quantification of western blots of Tau-P301L patient derived neurons, for the respective protein bands, normalized to Actin and shown relative to DMSO.
[0023] FIGs. 11A-11B are a series of graphs showing the effect of high concentration of T807 co-treatment with JWJ-1-96, JWJ-1-115, JWJ-1-123, JWJ-1-85, or JWJ-1-257, at the indicated concentrations, on the amount of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262 or pPP2A Y307, total PP2A, and ratios thereof. Relative levels were determined via densitometric quantification of western blots of Tau-P301L patient derived neurons, for the respective protein bands, normalized to Actin and shown relative to DMSO.
[0024] FIGs. 12A-12B are a series of graphs showing the effect of okadaic acid (O.A.) co- treatment with JWJ-1-96, JWJ-1-115, JWJ-1-123, JWJ-1-85, or JWJ-1-257, at the indicated concentrations, on the amount of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262 or pPP2A Y307, total PP2A, and ratios thereof. Relative levels were determined via densitometric quantification of western blots of Tau-P301L patient derived neurons, for the respective protein bands, normalized to Actin and shown relative to DMSO.
[0025] FIGs. 13A-13B are a series of graphs showing the effect of LB100 co-treatment with JWJ-1-96, JWJ-1-115, JWJ-1-123, JWJ-1-85, or JWJ-1-257, at the indicated concentrations, on the amount of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262 or pPP2A Y307, total PP2A, and ratios thereof. Relative levels were determined via densitometric quantification of western blots of Tau-P301L patient derived neurons, for the respective protein bands, normalized to Actin and shown relative to DMSO.
[0026] FIGs. 14A-14B are a series of graphs showing the effect of fostriecin co-treatment with JWJ-1-96, JWJ-1-115, JWJ-1-123, JWJ-1-85, or JWJ-1-257, at the indicated concentrations, on the amount of total Tau (TAU5), pTau AT8 (S202 / T205), and pTau S262or pPP2A Y307, total PP2A, and ratios thereof. Relative levels were determined via densitometric quantification of western blots of Tau-P301L patient derived neurons, for the respective protein bands, normalized to Actin and shown relative to DMSO. DETAILED DESCRIPTION
[0027] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present technology are described below in various levels of detail in order to provide a substantial understanding of the present technology. The definitions of certain terms as used in this specification are provided below. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this present technology belongs.
[0028] In practicing the present technology, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology and recombinant DNA are used. These techniques are well-known and are explained in, e.g., Current Protocols in Molecular Biology, Vols. I-III, Ausubel, Ed. (1997); Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989); DNA Cloning: A Practical Approach, Vols. I and II, Glover, Ed. (1985); Oligonucleotide Synthesis, Gait, Ed. (1984); Nucleic Acid Hybridization, Hames & Higgins, Eds. (1985); Transcription and Translation, Hames & Higgins, Eds. (1984); Animal Cell Culture, Freshney, Ed. (1986); Immobilized Cells and Enzymes (IRL Press, 1986); Perbal, A Practical Guide to Molecular Cloning; the series, Meth. Enzymol., (Academic Press, Inc., 1984); Gene Transfer Vectors for Mammalian Cells, Miller & Calos, Eds. (Cold Spring Harbor Laboratory, N Y, 1987); and Meth. Enzymol., Vols. 154 and 155, Wu & Grossman, and Wu, Eds., respectively.
[0029] In general, “substituted” refers to an alkyl, alkenyl, alkynyl, aryl, or ether group, as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom. Thus, a substituted group will be substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Illustrative substituent groups include: halogens (i.e., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, alkynoxy, aryloxy, aralkyloxy, heterocyclyloxy, andheterocyclylalkoxy groups; carbonyls (oxo); carboxyls; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like.
[0030] As used herein, “alkyl” groups include straight chain and branched alkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. As employed herein, “alkyl groups” include cycloalkyl groups as defined below. Alkyl groups may be substituted or unsubstituted. Examples of straight chain alkyl groups include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, sec-butyl, t-butyl, neopentyl, and isopentyl groups. Representative substituted alkyl groups may be substituted one or more times with, for example, amino, thio, hydroxy, cyano, alkoxy, and / or halo groups such as F, Cl, Br, and I groups. As used herein the term haloalkyl is an alkyl group having one or more halo groups. In some embodiments, haloalkyl refers to a per-haloalkyl group.
[0031] Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 6, or 7. Cycloalkyl groups may be substituted or unsubstituted. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to: 2,2-; 2,3-; 2,4-; 2,5-; or 2,6- disubstituted cyclohexyl groups or mono-, di-, or tri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, alkyl, alkoxy, amino, thio, hydroxy, cyano, and / or halo groups.
[0032] Alkenyl groups are straight chain, branched or cyclic alkyl groups having 2 to about 20 carbon atoms, and further including at least one double bond. In some embodiments alkenyl groups have from 1 to 12 carbons, or, typically, from 1 to 8 carbon atoms. Alkenyl groups may be substituted or unsubstituted. Alkenyl groups include, for instance, vinyl,propenyl, 2-butenyl, 3-butenyl, isobutenyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl groups among others. Alkenyl groups may be substituted similarly to alkyl groups. Divalent alkenyl groups, i.e., alkenyl groups with two points of attachment, include, but are not limited to, CH-CH=CH2, C=CH2, or C=CHCH3.
[0033] As used herein, “aryl”, or “aromatic,” groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Aryl groups include monocyclic, bicyclic and polycyclic ring systems. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenylenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups. The phrase “aryl groups” includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like). Aryl groups may be substituted or unsubstituted.
[0034] Certain compounds of the present application can exist in unsolvated forms as well as solvated forms, including hydrated forms. Solvated forms can exist, for example, because it is difficult or impossible to remove all the solvent from the compound post-synthesis. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present application. Certain compounds of the present application may exist in multiple crystalline or amorphous forms. Certain compounds of the present application may exist in various tautomeric forms. Certain compounds of the present application may exist in various salt forms. In general, all physical forms are equivalent for the uses contemplated by the present application and are intended to be within the scope of the present disclosure.
[0035] As used herein, the term "hydrate" refers to a compound which is associated with water. The number of the water molecules contained in a hydrate of a compound may be (or may not be) in a definite ratio to the number of the compound molecules in the hydrate.
[0036] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a therapeutically active compound that can be prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable baseaddition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Salts derived from pharmaceutically acceptable inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-methylmorpholine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine (NEt3), trimethylamine, tripropylamine, tromethamine and the like, such as where the salt includes the protonated form of the organic base (e.g., [HNEt3]+). Salts derived from pharmaceutically acceptable inorganic acids include salts of boric, carbonic, hydrohalic (hydrobromic, hydrochloric, hydrofluoric or hydroiodic), nitric, phosphoric, sulfamic and sulfuric acids. Salts derived from pharmaceutically acceptable organic acids include salts of aliphatic hydroxyl acids (e.g., citric, gluconic, glycolic, lactic, lactobionic, malic, and tartaric acids), aliphatic monocarboxylic acids (e.g., acetic, butyric, formic, propionic and trifluoroacetic acids), amino acids (e.g., aspartic and glutamic acids), aromatic carboxylic acids (e.g., benzoic, p-chlorobenzoic, diphenylacetic, gentisic, hippuric, and triphenylacetic acids), aromatic hydroxyl acids (e.g., o-hydroxybenzoic, p-hydroxybenzoic, 1-hydroxynaphthalene-2-carboxylic and 3-hydroxynaphthalene-2-carboxylic acids), ascorbic, dicarboxylic acids (e.g., fumaric, maleic, oxalic and succinic acids), glucuronic, mandelic, mucic, nicotinic, orotic, pamoic, pantothenic, sulfonic acids (e.g., benzenesulfonic, camphorsulfonic, edisylic, ethanesulfonic, isethionic, methanesulfonic, naphthalenesulfonic, naphthalene-1,5-disulfonic, naphthalene-2,6-disulfonic, p-toluenesulfonic acids (PTSA)), xinafoic acid, and the like. In some embodiments, the pharmaceutically acceptable counterion is selected from the group consisting of acetate, benzoate, besylate, bromide, camphorsulfonate, chloride, chlorotheophyllinate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucoronate, hippurate, iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, mesylate, methylsulfate, naphthoate, sapsylate, nitrate, octadecanoate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate,sulfosalicylate, tartrate, tosylate, and trifluoroacetate. In some embodiments, the salt is a tartrate salt, a fumarate salt, a citrate salt, a benzoate salt, a succinate salt, a suberate salt, a lactate salt, an oxalate salt, a phthalate salt, a methanesulfonate salt, a benzenesulfonate salt, a maleate salt, a trifluoroacetate salt, a hydrochloride salt, or a tosylate salt. Also included are salts of amino acids such as arginate and the like, and salts of organic acids such as glucuronic or galactunoric acids and the like (see, e.g., Berge et al, Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present application may contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts or exist in zwitterionic form. These salts may be prepared by methods known to those skilled in the art. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present technology.
[0037] As used herein, the term "small molecule" refers to^any compound that affects a biologic process with a molecular weight less than about 1,000 daltons. It is to be understood that for purposes of this definition, the molecular mass is calculated without reference to any associated (i.e., non-covalently bonded) molecules such as salts, water or other solvent molecules.
[0038] As used herein, the term "solvate" refers to forms of the compound that are associated with a solvent, possibly by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, isopropanol, acetic acid, ethyl acetate, acetone, hexane(s), DMSO, THF, diethyl ether, and the like.
[0039] As used herein, the term "tautomer" refers to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of S electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Tautomeric forms may be relevant to the attainment of the optimal c1emical reactivity and biological activity of a compound of interest.
[0040] Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Compounds comprising radioisotopes such as tritium, C14, P32and S35are thus within the scope of the present technology. Procedures for insertingsuch labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
[0041] Groups described herein having two or more points of attachment (i.e., divalent, trivalent, or polyvalent) within the compound of the present technology are designated by use of the suffix, “ene.” For example, divalent alkyl groups are alkylene groups, divalent aryl groups are arylene groups, divalent heteroaryl groups are divalent heteroarylene groups, and so forth. Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the “ene” designation. Thus, e.g., chloroethyl is not referred to herein as chloroethylene. Such groups may further be substituted or unsubstituted.
[0042] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the technology are described below in various levels of detail in order to provide a substantial understanding of the present application. The definitions of certain terms as used in this specification are provided below. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs.
[0043] As used in this specification and the appended embodiments, the singular forms “a,” “an” and “the” include plural references unless the content clearly dictates otherwise. For example, reference to “a cell” includes a combination of two or more cells, and the like.
[0044] As utilized herein with respect to numerical ranges, the terms “approximately,” “about,” “substantially,” and similar terms will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the terms that are not clear to persons of ordinary skill in the art, given the context in which it is used, the terms will be plus or minus 10% of the disclosed values. When “approximately,” “about,” “substantially,” and similar terms are applied to a structural feature (e.g., to describe its shape, size, orientation, direction, etc.), these terms are meant to cover minor variations in structure that may result from, for example, the manufacturing or assembly process and are intended to have a broad meaning in harmony with the common and accepted usage by those of ordinary skill in the art to which the subject matter of this disclosure pertains. Accordingly, these terms should be interpreted as indicating that insubstantial or inconsequential modifications or alterations of the subject matter describedand claimed are considered to be within the scope of the disclosure as recited in the appended claims.
[0045] As used herein, the “administering” or the “administration” of an agent (i.e. therapeutic agent) or compound / drug product (including a composition) to a subject includes any route of introducing or delivering to a subject a compound / drug product to perform its intended function. Administration may be carried out by any suitable route, such as oral administration. Administration can be carried out subcutaneously. Administration can be carried out intravenously. Administration can be carried out intraocularly. Administration can be carried out systemically. Alternatively, administration may be carried out topically, intranasally, intraperitoneally, intradermally, ophthalmically, intrathecally, intracerebroventricularly, iontophoretically, transmucosally, intravitreally, or intramuscularly. Administration includes self-administration, the administration by another or administration by use of a device (e.g., an infusion pump).
[0046] As used herein, to “ameliorate” or “ameliorating” a disease, disorder or condition (e.g., a tauopathy) refers to results that, in a statistical sample or specific subject, make the occurrence of the disease, disorder or condition (or a sign, symptom or condition thereof) better or more tolerable in a sample or subject administered a therapeutic agent relative to a control sample or subject.
[0047] As used herein the terms “carrier” and “pharmaceutically acceptable carrier” refer to a diluent, adjuvant, excipient, or vehicle with which a compound / drug product / composition (including a medicament) is administered or formulated for administration. Non-limiting examples of such pharmaceutically acceptable carriers include liquids, such as water, saline, oils and solids, such as gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, silica particles (nanoparticles or microparticles) urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, flavoring, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences by E.W. Martin, herein incorporated by reference in its entirety.
[0048] As used herein, the phrase “delaying the onset of” refers to, in a statistical sample, postponing, hindering the occurrence of a disease, disorder or condition, or causing one or more signs, symptoms or conditions of a disease, disorder or condition to occur more slowly than normal, in a sample or subject administered a therapeutic agent relative to a control sample or subject.
[0049] As used herein, the term “effective amount” refers to a quantity of a compound / composition / drug product sufficient to achieve a desired therapeutic and / or prophylactic effect, e.g., an amount that treats, prevents, inhibits, ameliorates, or delays the onset of the disease, disorder or condition, or the physiological signs, symptoms or conditions of the disease or disorder. In the context of therapeutic or prophylactic applications, in some embodiments, the amount of a compound / composition / drug product administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. In some embodiments, it will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
[0050] In some of the methods described herein, the compounds of the present disclosure, or pharmaceutically acceptable salts, tautomers, hydrates, and / or solvates thereof, may be administered to a subject having one or more signs, symptoms, or conditions associated with a tauopathy. For example, a “therapeutically effective amount” of a compound of the present disclosure includes levels at which the presence, frequency, or severity of one or more signs, symptoms, or conditions (e.g., risk factors) of a disease or disorder associated with a tauopathy, are treated, prevented, inhibited, ameliorated or delayed in a subject. In some embodiments, administration of a therapeutically effective amount of a compound of the present disclosure treats, inhibits, ameliorates, prevents or delays in a subject the physiological effects of a disease, disorder or condition associated with a tauopathy.
[0051] As used herein, “inhibit” or “inhibiting” refers to the reduction in a sign, symptom or condition (e.g. risk factor) associated with a disease, disorder or condition associated with a tauopathy by an objectively measurable amount or degree compared to a control. In one embodiment, inhibit or inhibiting refers to the reduction by at least a statistically significant amount compared to a control (or control subject). In one embodiment, inhibit or inhibiting refers to a reduction by at least 5 percent compared to control (or control subject). In various individual embodiments, inhibit or inhibiting refers to a reduction by at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 33, 40, 50, 60, 67, 70, 75, 80, 90, 95, or 99 percent compared to a control (or control subject).
[0052] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.
[0053] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.
[0054] As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this definition.
[0055] As used herein, a “subject” refers to a living animal. In various embodiments, a subject is a mammal. In various embodiments, a subject is a non-human mammal, including, without limitation, a mouse, rat, hamster, guinea pig, rabbit, sheep, goat, cat, dog, pig, minipig, horse, cow, or non-human primate. In certain embodiments, the subject is a human.
[0056] As used herein, the terms “treating” or “treatment” refer to therapeutic treatment, wherein the object is to reduce, alleviate or slow down (lessen) a pre-existing disease or disorder, or its related signs, symptoms or conditions. By way of example, but not by way of limitation, a subject is successfully “treated” for a disease (e.g., tauopathy) if, after receiving an effective amount of the compound / composition / drug product or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof, the subject shows observable and / or measurable reduction in or absence of one or more signs, symptoms or conditions associated with the disease, disorder or condition (e.g., tauopathy). For example, treatment of a subject may reduce Tau species levels and / or reduce the toxicity associated with cellular Tau accumulation in the subject. Treatment may also, for example, reduce cellular oxidative stress caused by cellular accumulation of Tau protein. It is also to be appreciated that the various modes of treatment of medical conditions as described are intended to mean “substantial,” which includes total alleviation of conditions, signs or symptoms of the disease or disorder, as well as “partial,” where some biologically or medically relevant result is achieved.
[0057] As used herein, “prevention” or “preventing” of a disease, disorder, or condition associated with a tauopathy refers to results that, in a statistical sample, exhibit a reduction in the occurrence of the disease, disorder, or condition in a sample or subject administered atherapeutic agent relative to a control sample or subject, or exhibit a delay in the onset of one or more symptoms of the disease, disorder, or condition relative to the control sample or subject. Such prevention is sometimes referred to as a prophylactic treatment.
[0058] In one aspect, the present disclosure describes bifunctional small molecules that trigger dephosphorylation of Tau proteins by recruiting endogenous PP2A phosphatase to Tau aggregates. The small molecules consist of a Tau binder, a linker and a PP2A binder or activator. The present disclosure shows that the small molecules reduce levels of phosphorylated tau, in a neuronal model for Tau aggregation, thereby reducing the ratio of P- tau / total tau. Some of the small molecules primarily caused dephosphorylation of P-Tau AT8, while other small molecules also caused dephosphorylation of P-Tau S262.
[0059] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.
[0060] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.
[0061] As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this definition. I. Tauopathies
[0062] Tauopathies is an umbrella term encompassing a number of neurodegenerative disorders that are characterized by Tau deposits in the brain and central nervous systems. In certain Tauopathies the Tau deposits also contain other proteins at various abundances, such as beta-amyloid. Mutations to the microtubule-associated protein Tau encoded by the MAPT gene that encodes Tau can lead to the pathogenic isoforms 3R and 4R and deposits that are made up of 3R, 4R, or a mix therein. At least the following mutations are known to be pathogenic: R5H, R5L, G55R, A152T, K257T, I260V, L266V, G272V, G273R, N279K, K280del, L284L, L284R, S285R, C291R, N296del, N296D, N296H, N296N, P301L, P301S,P301T, G303V, S305I, S305N, S305S, L315L, L315R, K317M, K317N, S320F, S320Y, P332S, G335A, G335S, G335V, Q336H, Q336R, V337M, E342V, S352L, S356T, V363I, P364S, G366R, K369I, E372G, G389R, P397S, R406W, R406G, and N410H. Aberrant Tau phosphorylation is an important disease process, influencing Tau structure, distribution, and function in neurons. Heavily phosphorylated Tau deposits can occur in multiple locations, including neurons, glial cells, and extracellular space. Tauopathies are further characterized by symptoms including, but not limited to: disinhibition, apathy, loss of empathy, stereotypic behaviours, hyperorality, memory loss, difficulty communicating and reasoning, confusion, loss of coordination, depression, anxiety, paranoia, agitation, hallucinations, postural instability, vertical supranuclear ophthalmoplegia, asymmetrical limb apraxia, cortical function deficits, asymmetric onset of tremor, bradykinesia, rigidity, cerebellar ataxia, difficulty speaking, anomia, impaired comprehension, phonemic paraphasia, motor speech disorder, visuospatial disorientation, impaired executive abilities, or any combination thereof. At a cellular level, signs of tauopathies include Tau deposits, elevated reactive oxygen species levels, and neuronal degradation.
[0063] Numerous tauopathies have been identified to date, including: Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism–dementia complex, anti-IgLON5-related tauopathy, Caribbean Parkinsonism, chronic traumatic encephalopathy, diffuse neurofibrillary tangles with calcification, progressive supranuclear palsy, Down syndrome, Familial British dementia, Familial Danish dementia, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, postencephalitic Parkinsonism, primary age-related tauopathy, progressive ataxia, palatal tremor, neurofibrillary dementia, familial frontotemporal dementia, Parkinsonism, Pick's disease, argyrophilic grain disease, corticobasal degeneration, Guadeloupean Parkinsonism, globular glial tauopathy, Huntington's Disease, SLC9a-related Parkinsonism, and aging-related Tau astrogliopathy. Despite the prevalence of tauopathies, most still lack effective treatment options. For example, dementia afflicts more than 55 million people worldwide, but there are limited treatment options available and no cure.
[0064] Diagnosis of tauopathies is challenging and autopsy is one of the few definitive diagnostic methods. See Coughlin D, Irwin DJ. Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep. 2017 Sep;17(9):72. Subjects at risk for or predisposed for the development of a tauopathy can be identified by, e.g., any one or acombination of diagnostic or prognostic assays known in the art. Various tauopathies may be diagnosed by a combination of symptoms and the results of certain tests to rule out other conditions before making a diagnosis, including through the use of neuropathologic evaluation (through the detection of extracellular Tau plaques and intracellular neurofibrillary tangles in brain tissue). Medical evaluations typically include patient history, physical examination, and neuropsychological testing. Familial medical history and genetic counseling may also be of use. For example, the APOE4 risk allele is associated with higher chances of individuals over the age of 55 years developing Alzheimer’s disease and could indicate the likelihood of developing the disease. To diagnose a subject as having a tauopathy, tests involving memory, problem solving, attention, counting, language, balance, senses, and reflexes may be conducted. Standard medical tests, such as blood and urine tests, or brain scans may be conducted to rule out other possible causes of the symptoms. New and emerging diagnostic methods include structural neuroimaging, molecular imaging, and biofluid biomarker analysis, particularly of cerebrospinal fluid. Additional emerging tests may also enable the assessment of biomarkers in people who may be at risk of a tauopathy.
[0065] Cellular models have been developed to study tauopathies, including the P301L MAPT neuronal cell model. Induced pluripotent stem cell (iPSC)-derived neural progenitor cells (NPCs) are derived from a patient carrier of the Tau-P301L autosomal dominant mutation. Post-mitotic neurons are generated from the patients’ NPCs and are subsequently differentiated into neurons enriched for cortical neuron subtypes for a period of 6 to 8 weeks, as previously described (Cheng et al., 2017; Silva et al., 2016; Seo et al., 2017). The P301L model exhibits expresses Tau at endogenous levels (i.e., they do not rely on an artificial, engineered transgene overexpressing the protein), recapitulates disease-relevant Tau phenotypes ex vivo, and present a valuable opportunity to tests new therapeutics directly against a clinically relevant model of human disease. Therefore, the P301L model provides a useful human genomic background for testing the efficacy of new therapeutics that treat tauopathies. II. Pharmaceutical Compositions, Routes of Administration, and Dosing:
[0066] In some embodiments, the present application is directed to a pharmaceutical composition. In some embodiments, the composition comprises a compound of the present application and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a plurality of compounds of the present applicationand a pharmaceutically acceptable carrier. The pharmaceutical composition can be a medicament.
[0067] Pharmaceutical compositions of the present application may contain an effective amount of a therapeutic compound / agent (or compounds / agents) as described herein and may optionally be disbursed (e.g. dissolved, suspended or otherwise) in a pharmaceutically acceptable carrier. The components of the pharmaceutical composition(s) may also be capable of being commingled with the compounds of the present application, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficiency.
[0068] As stated above, an “effective amount” refers to any amount of the active compound (or compounds; alone or as formulated) that is sufficient to achieve a desired biological effect. Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and mode of administration, an effective prophylactic (i.e. preventative) or therapeutic treatment regimen can be planned which does not cause substantial unwanted toxicity and yet is effective to treat the particular condition or disease of a particular subject. The effective amount for any particular indication can vary depending on such factors as the disease, disorder or condition being treated, the particular compound or compounds being administered, the size of the subject, or the severity of the disease, disorder or condition. The effective amount may be determined during pre-clinical trials and / or clinical trials by methods familiar to physicians and clinicians. One of ordinary skill in the art can empirically determine the effective amount of a particular compound and / or other therapeutic agent(s) without necessitating undue experimentation. A maximum dose may be used, that is, the highest safe dose according to some medical judgment. Multiple doses per day may be contemplated to achieve appropriate systemic levels of compounds. Appropriate systemic levels can be determined by, for example, measurement of the patient’s peak or sustained plasma level of the drug. “Dose” and “dosage” are used interchangeably herein. A dose may be administered by oneself, by another or by way of a device (e.g. a pump).
[0069] For any compound described herein the therapeutically effective amount can, for example, be initially determined from animal models. A therapeutically effective dose can also be determined from human data for compounds which have been tested in humans and for compounds which are known to exhibit similar pharmacological activities, such as other related active agents. Higher doses may be required for parenteral administration. Theapplied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.
[0070] Compounds (alone or as formulated in a pharmaceutical composition) for use in therapy or prevention can be tested in suitable animal model systems. Suitable animal model systems include, but are not limited to, rats, mice, chicken, cows, monkeys, rabbits, pigs, minipigs and the like, prior to testing in human subjects. In vivo testing, any of the animal model system known in the art can be used prior to administration to human subjects. In some embodiments, dosing can be tested directly in humans.
[0071] Dosage, toxicity and therapeutic efficacy of any therapeutic compounds / agents, compositions (e.g. formulations or medicaments), other therapeutic agents, or mixtures thereof can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50 / ED50. Compounds that exhibit high therapeutic indices are advantageous. While compounds that exhibit toxic side effects may be used, in such cases it may be prudent to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
[0072] In some embodiments, an effective amount of a therapeutic compound / agent disclosed herein sufficient for achieving a therapeutic or prophylactic effect, can range from about 0.000001 mg per kilogram body weight per day to about 10,000 mg per kilogram body weight per day. Suitably, the dosage ranges are from about 0.0001 mg per kilogram body weight per day to about 100 mg per kilogram body weight per day. For example dosages can be 1 mg / kg body weight or 100 mg / kg body weight every day, every two days or every three days or within the range of 1-100 mg / kg every week, every two weeks or every three weeks. In some embodiments, a single dosage of a therapeutic compound / agent disclosed herein ranges from 0.001-10,000 micrograms per kg body weight. In some embodiments, a therapeutic compound / agent disclosed herein dissolved or suspended in a carrier range from 0.2 to 2000 micrograms per delivered milliliter. In some embodiments, the dose regimenmeets pharmacokinetic target concentrations in target tissues to achieve a desired therapeutic outcome.
[0073] An exemplary treatment regime can entail administration once per day, twice per day, thrice per day, once a week, or once a month. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until the progression of the disease is reduced or terminated, or until the subject shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regimen.
[0074] In some embodiments, a therapeutically effective amount of a therapeutic compound / agent disclosed herein may be defined as a concentration of compound existing at the target tissue of 10-12to 10-4molar, e.g., approximately 10-7molar. This concentration may be delivered by systemic doses of 0.001 to 100 mg / kg or equivalent dose by body surface area. The schedule of doses would be optimized to maintain the therapeutic concentration at the target tissue, such as by single daily or weekly administration, but also including continuous administration (e.g., central nervous system directed, oral, systemic, topical, subcutaneous, intra-nasal, parenteral infusion or transdermal application).
[0075] In some embodiments, the compounds the compounds of the present disclosure are administered to directly to the central nervous system, for example via intrathecal, intracerebroventricular administration or wafer insertion. In some embodiments, intrathecal, intracerebroventricular administration, or wafer insertion administration of a compound (alone or as formulated) may be from about 0.000001 mg per kilogram body weight per day to about 10,000 mg per kilogram body weight per day. In some embodiments, intrathecal, intracerebroventricular administration, or wafer insertion administration of a compound (alone or as formulated) may be from about 5 mg per kilogram body weight per day to about 1000 mg per kilogram body weight per day. In some embodiments, intrathecal, intracerebroventricular administration, or wafer insertion administration of a compound (alone or as formulated) may be from about 50 mg per kilogram body weight per day to about 100 mg per kilogram body weight per day.
[0076] In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 0.01 Pg / kg / day to 1000 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 0.01 Pg / kg / day to 100 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) maytypically be from 0.1 Pg / kg / day to 10 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 10 Pg / kg / day to 2 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 500 Pg / kg / day to 5 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 1 mg / kg / day to 100 mg / kg / day. In some embodiments, intravenous or subcutaneous administration of a compound (alone or as formulated) may typically be from 1 mg / kg / day to 50 mg / kg / day.
[0077] Generally, daily oral doses of a compound (alone or as formulated) will be, for human subjects, from about 0.01 micrograms / kg per day to 250 milligrams / kg per day. In some embodiments, daily oral doses of a compound (alone or as formulated) will be, for human subjects, from about 1 milligrams / kg per day to 100 milligrams / kg per day or from about 10 milligrams / kg per day to 75 milligrams / kg per day or It is expected that oral doses of a compound (alone or as formulated) in the range of 0.1 to 50 milligrams / kg, in one or more administrations per day, will yield therapeutic results. Dosage may be adjusted appropriately to achieve desired drug levels, local or systemic, depending upon the mode of administration. For example, it is expected that intravenous administration would be from one order to several orders of magnitude lower dose per day. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of the compound.
[0078] For use in therapy, an effective amount of the compound (alone or as formulated) can be administered to a subject by any mode that delivers the compound to the desired surface. Administering a pharmaceutical composition may be accomplished by any means known to the skilled artisan. Routes of administration include but are not limited to intracerebroventricular, wafer insertion, oral, topical, intranasal, systemic, intravenous, subcutaneous, intraperitoneal, intradermal, intraocular, ophthalmical, intrathecal, iontophoretical, transmucosal, intravitreal, or intramuscular administration. Administration includes self-administration, the administration by another person and administration by a device.
[0079] A therapeutic compound / agent disclosed herein can be delivered to the subject in a formulation or medicament (i.e. a pharmaceutical composition). Formulations and medicaments can be prepared by, for example, dissolving or suspending a therapeutic compound / agent disclosed herein in water, a pharmaceutically acceptable carrier, salt, (e.g. NaCl or sodium phosphate), buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutically acceptable ingredients.
[0080] The pharmaceutical compositions (e.g. a formulation or medicament) can include a carrier (e.g. a pharmaceutically acceptable carrier), which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thiomerasol, and the like. Glutathione and other antioxidants can be included to prevent oxidation. In many cases, it will be advantageous to include isotonic agents, for example, sugars (e.g. trehalose), polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate or gelatin.
[0081] Solutions or suspensions (e.g. a formulation or medicament) used for parenteral, intradermal, subcutaneous or intraocular application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. For convenience of the patient or treating physician, the dosing formulation can be provided alone or in a kit containing all necessary equipment (e.g., vials of drug, vials of diluent, syringes and needles) for a treatment course (e.g., 1, 2, 3, 4, 5, 6, 7 days or more of treatment).
[0082] The therapeutic compounds / agents or pharmaceutical compositions, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion (for example by IV injection or via a pump to meter the administration over a defined time). Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[0083] Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.
[0084] For intravenous and other parenteral routes of administration, a compound can be formulated as a lyophilized preparation, as a lyophilized preparation of liposome-intercalated or -encapsulated active compound, as a lipid complex in aqueous suspension, or as a salt complex. Lyophilized formulations are generally reconstituted in suitable aqueous solution, e.g., in sterile water or saline, shortly prior to administration.
[0085] Pharmaceutical compositions (e.g. a formulation or medicament) suitable for injection can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). A composition for administration by injection will generally be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms such as bacteria and fungi.
[0086] Sterile injectable solutions (e.g. a formulation or medicament) can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, typical methods of preparation include vacuum drying and freeze drying, which can yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0087] For oral administration, the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the present application to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel£, or corn starch; a lubricant such as magnesium stearate or sterates; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[0088] Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers, e.g., EDTA for neutralizing internal acid conditions or may be administered without any carriers.
[0089] Also specifically contemplated are oral dosage forms of the above that may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to thetherapeutic agent(s), ingredient(s), and / or excipient(s), where said moiety permits (a) inhibition of acid hydrolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the therapeutic agent(s), ingredient(s), and / or excipient(s) and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts”, In: Enzymes as Drugs, Hocenberg and Roberts, eds., Wiley-Interscience, New York, N.Y., pp. 367-383 (1981); Newmark et al., J Appl Biochem 4:185-9 (1982). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. For pharmaceutical usage, as indicated above, polyethylene glycol (PEG) moieties of various molecular weights are suitable.
[0090] For the formulation of the therapeutic agent(s), ingredient(s), and / or excipient(s), the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the compound of the present application (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.
[0091] A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic (e.g., powder); for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.
[0092] The therapeutic compound / agent or pharmaceutical composition can be included in the formulation as fine multi-particulates in the form of granules or pellets of particle size about 1-2 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic compound / agent or pharmaceutical composition could be prepared by compression.
[0093] Colorants and flavoring agents may all be included. For example, the compound or pharmaceutical composition of the present application (or derivative) may be formulated andthen further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.
[0094] One may dilute or increase the volume of the therapeutic compound / agent or pharmaceutical composition with an inert material. These diluents could include carbohydrates, especially mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo£, Emdex£, STARCH 1500£, Emcompress£ and Avicel£.
[0095] Disintegrants may be included in the formulation of the therapeutic compound / agent or composition into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite£, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, karaya gum or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
[0096] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.
[0097] An anti-frictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol (PEG) of various molecular weights, Carbowax™ 4000 and 6000.
[0098] Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
[0099] To aid dissolution of the therapeutic compound / agent or composition (e.g. medicament) into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents which can be used and can include benzalkonium chloride and benzethonium chloride. Potential non-ionic detergents that could be included in the formulation as surfactants include lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the compound of the present application or derivative either alone or as a mixture in different ratios.
[0100] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.
[0101] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
[0102] For topical administration, the compound may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art. Solutions, gels, ointments, creams or suspensions may be administered topically. The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
[0103] For administration by inhalation, compounds or compositions (e.g. medicament) for use according to the present application may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In some embodiments, the formulation, medicament or therapeutic compound / agent can be delivered in the form of an aerosol spray from apressurized container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. For example, capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the therapeutic compound / agent and a suitable powder base such as lactose or starch. Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0104] Nasal delivery of a therapeutic compound / agent or pharmaceutical composition of the present application is also contemplated. Nasal delivery allows the passage of a therapeutic compound / agent or pharmaceutical composition to the blood stream directly after administering the therapeutic compound / agent or pharmaceutical composition to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextrin.
[0105] For nasal administration, a useful device is a small, hard bottle to which a metered dose sprayer is attached. In some embodiments, the metered dose is delivered by drawing the pharmaceutical composition of the present application solution into a chamber of defined volume, which chamber has an aperture dimensioned to aerosolize and aerosol formulation by forming a spray when a liquid in the chamber is compressed. The chamber is compressed to administer the therapeutic compound / agent or pharmaceutical composition. In a specific embodiment, the chamber is a piston arrangement. Such devices are commercially available.
[0106] Alternatively, a plastic squeeze bottle with an aperture or opening dimensioned to aerosolize an aerosol formulation by forming a spray when squeezed is used. The opening is usually found in the top of the bottle, and the top is generally tapered to partially fit in the nasal passages for efficient administration of the aerosol formulation. Preferably, the nasal inhaler will provide a metered amount of the aerosol formulation, for administration of a measured dose of the therapeutic compound / agent or pharmaceutical composition.
[0107] Also contemplated herein is pulmonary delivery of the compounds disclosed herein. The compound or pharmaceutical composition is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. Other reports ofinhaled molecules include Adjei et al., Pharm Res 7:565-569 (1990); Adjei et al., Int J Pharmaceutics 63:135-144 (1990) (leuprolide acetate); Braquet et al., J Cardiovasc Pharmacol 13(suppl. 5):143-146 (1989) (endothelin-1); Hubbard et al., Annal Int Med 3:206- 212 (1989) (α1-antitrypsin); Smith et al., 1989, J Clin Invest 84:1145-1146 (a-1-proteinase); Oswein et al., 1990, “Aerosolization of Proteins” Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado, March, (recombinant human growth hormone); Debs et al., 1988, J Immunol 140:3482-3488 (interferon-gamma and tumor necrosis factor alpha) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor; incorporated by reference). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Pat. No. 5,451,569 (incorporated by reference), issued Sep. 19, 1995 to Wong et al.
[0108] Contemplated for use in the practice of this disclosure are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
[0109] Some specific examples of commercially available devices suitable for the practice of this disclosure are the Ultravent™ nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II£ nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin£ metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler£ powder inhaler, manufactured by Fisons Corp., Bedford, Mass.
[0110] All such devices require the use of formulations suitable for the dispensing of the compound(s) / therapeutic agent(s). Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and / or carriers useful in therapy. Also, the use of liposomes, microcapsules, microspheres, nanoparticles, nanospheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified compound of the present application may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.
[0111] Formulations suitable for use with a nebulizer, either jet or ultrasonic, can, for example, comprise a compound / therapeutic agent of the present application (or derivative) dissolved in water at a concentration of about 0.01 to 50 mg of biologically active compoundper mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for inhibitor stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the compound of the present application caused by atomization of the solution in forming the aerosol.
[0112] Formulations for use with a metered-dose inhaler device may generally comprise a finely divided powder containing the compound of the present application (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2- tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.
[0113] Formulations for dispensing from a powder inhaler device may comprise a finely divided dry powder containing compound of the present application (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The compound(s) / therapeutic agent(s) of the present application (or derivative) can advantageously be prepared in particulate or nanoparticulate form with an average particle size of less than 10 micrometers (Pm), mIVost preferably 0.5 to 5 Pm, for most effective delivery to the deep lung.
[0114] For ophthalmic or intraocular indications, any suitable mode of delivering the therapeutic compounds / agents or pharmaceutical compositions to the eye or regions near the eye can be used. For ophthalmic formulations generally, see Mitra (ed.), Ophthalmic Drug Delivery Systems, Marcel Dekker, Inc., New York, N.Y. (1993) and also Havener, W. H., Ocular Pharmacology, C.V. Mosby Co., St. Louis (1983). Nonlimiting examples of pharmaceutical compositions suitable for administration in or near the eye include, but are not limited to, ocular inserts, minitablets, and topical formulations such as eye drops, ointments, and in situ gels. In one embodiment, a contact lens is coated with a pharmaceutical composition comprising a therapeutic compound / agent disclosed herein. In some embodiments, a single dose can comprise from between 0.1 ng to 5000 μg, 1 ng to 500 μg, or 10 ng to 100 μg of the therapeutic compounds / agents or pharmaceutical compositions administered to the eye.
[0115] Eye drops can comprise a sterile liquid formulation that can be administered directly to the eye. In some embodiments, eye drops comprise at least one therapeutic compound / agent disclosed herein and may further comprise one or more preservatives. In some embodiments, the optimum pH for eye drops equals that of tear fluid and is about 7.4. For eye drops, the therapeutic compound / agent can be present in the drop solution from about 0.1% to about 5% (w / v or v / v depending on the physical nature (i.e. solid or liquid) of the active ingredient). In some embodiments, the therapeutic compound / agent can be present in the drop solution from about 1% to about 3% (w / v or v / v, as appropriate).
[0116] In situ gels are viscous liquids, showing the ability to undergo sol-to-gel transitions when influenced by external factors, such as appropriate pH, temperature, and the presence of electrolytes. This property causes slowing of drug drainage from the eyeball surface and increase of the active ingredient bioavailability. Polymers commonly used in in situ gel formulations include, but are not limited to, gellan gum, poloxamer, silicone containing formulations, silica-based formulations and cellulose acetate phthalate. In some embodiments, the therapeutic compound / agent is formulated into an in-situ gel (as the pharmaceutical composition / medicament).
[0117] For topical ophthalmic administration, therapeutic compound / agent or pharmaceutical composition may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art. Ointments are semisolid dosage forms for external use such as topical use for the eye or skin. In some embodiments, ointments comprise a solid or semisolid hydrocarbon base of melting or softening point close to human core temperature. In some embodiments, an ointment applied to the eye decomposes into small drops, which stay for a longer time period in conjunctival sac, thus increasing bioavailability.
[0118] Ocular inserts are solid or semisolid dosage forms without disadvantages of traditional ophthalmic drug forms. They are less susceptible to defense mechanisms like outflow through nasolacrimal duct, show the ability to stay in conjunctival sac for a longer period, and are more stable than conventional dosage forms. They also offer advantages such as accurate dosing of one or more therapeutic compounds / agents, slow release of one or more therapeutic compounds / agents with constant speed and limiting of one or more therapeutic compounds’ / agents’ systemic absorption. In some embodiments, an ocular insert comprises one or more therapeutic compounds / agents as disclosed herein and one or more polymeric materials. The polymeric materials can include, but are not limited to, methylcellulose andits derivatives (e.g., hydroxypropyl methylcellulose (HPMC)), ethylcellulose, polyvinylpyrrolidone (PVP K-90), polyvinyl alcohol, chitosan, carboxymethyl chitosan, gelatin, and various mixtures of the aforementioned polymers. An ocular insert can comprise silica. An ocular insert can comprise liposomes, nanoparticles or microparticles of degradable or biodegradable polymer (as described in more detail below).
[0119] Minitablets are biodegradable, solid drug forms, that transit into gels after application to the conjunctival sac, thereby extending the period of contact between active ingredient (i.e. the therapeutic compounds / agents disclosed herein) and the eyeball surface, which in turn increases a therapeutic compounds’ / agents’ bioavailability. The advantages of minitablets include easy application to conjunctival sac, resistance to defense mechanisms like tearing or outflow through nasolacrimal duct, longer contact with the cornea caused by presence of mucoadhesive polymers, and gradual release of the active ingredient from the formulation in the place of application due to the swelling of the outer carrier layers. Minitablets can comprise one or more of the therapeutic compounds / agents disclosed herein and one or more polymers. Nonlimiting examples of polymers suitable for use in in a minitablet formulation include cellulose derivatives, like hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC), sodium carboxymethyl cellulose, ethyl cellulose, acrylates (e.g., polyacrylic acid and its cross-linked forms), Carbopol£ or carbomer, chitosan, and starch (e.g., drum-dried waxy maize starch). In some embodiments, minitablets further comprise one or more excipients. Nonlimiting examples of excipients include mannitol and magnesium stearate.
[0120] The ophthalmic or intraocular formulations and medicaments may contain non-toxic auxiliary substances such as antibacterial components which are non-injurious in use, for example, thimerosal, benzalkonium chloride, methyl and propyl paraben, benzyldodecinium bromide, benzyl alcohol, or phenylethanol; buffering ingredients such as sodium chloride, sodium borate, sodium acetate, sodium citrate, or gluconate buffers; and other conventional ingredients such as sorbitan monolaurate, triethanolamine, polyoxyethylene sorbitan monopalmitylate, ethylenediamine tetraacetic acid, and the like.
[0121] In some embodiments, the viscosity of the ocular formulation comprising one or more therapeutic compounds / agents is increased to improve contact with the cornea and bioavailability in the eye. Viscosity can be increased by the addition of hydrophilic polymers of high molecular weight which do not diffuse through biological membranes and which form three-dimensional networks in the water. Nonlimiting examples of such polymersinclude polyvinyl alcohol, poloxamers, hyaluronic acid, carbomers, and polysaccharides, cellulose derivatives, gellan gum, and xanthan gum.
[0122] In addition to the formulations described above, a therapeutic compound / agent disclosed herein may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[0123] In some embodiments, the therapeutic agent(s) is / are administered as a depot formulation wherein the active therapeutic agent(s) is / are encapsulated by, or disposed within, silica-based microparticles. In some embodiments, the ocular formulation can be injected into the eye, for example as a sol-gel (e.g. a silica sol-gel). In some embodiments, the ocular formulation is a depot formulation such as a controlled release formulation (see below). Such controlled release formulation may comprise particles, such as microparticles or nanoparticles.
[0124] The pharmaceutical compositions also may comprise suitable solid or gel-phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, silica / silicone and polymers such as polyethylene glycols.
[0125] Suitable liquid or solid pharmaceutical preparation forms can, for example, be aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and / or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions can be suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R, Science 249:1527-33 (1990).
[0126] The therapeutic agent(s), including specifically but not limited to a therapeutic compound / agent disclosed herein, may be provided in particles. Particles as used herein means nanoparticles or microparticles (or in some instances larger particles) which canconsist in whole or in part of the therapeutic compound / agent or the other therapeutic agent(s) as described herein. The particles may contain the therapeutic compound(s) / agent(s) in a core surrounded by a coating, including, but not limited to, an enteric coating. The therapeutic compound(s) / agent(s) also may be dispersed throughout the particles. The therapeutic compound(s) / agent(s) also may be adsorbed into the particles. The particles may be of any order release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, and any combination thereof, etc. The particle may include, in addition to the therapeutic compound(s) / agent(s), any of those materials routinely used in the art of pharmacy and medicine, including, but not limited to, erodible, non-erodible, biodegradable, or nonbiodegradable material or combinations thereof. The particles may be microcapsules which contain the therapeutic compound(s) / agent(s) in a solution or in a semi-solid state. The particles may be of virtually any shape.
[0127] Both non-biodegradable and biodegradable polymeric materials can be used in the manufacture of particles for delivering the therapeutic compound(s) / agent(s). Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired. Bioadhesive polymers of particular interest include bioerodible hydrogels described in Sawhney H S et al. (1993) Macromolecules 26:581-7, the teachings of which are incorporated herein. These include polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, polyethylene glycols (PEGs), polyvinylalcohols (PVAs), poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly-lactic acid (PLA), poly(lactic -co- glycolic) acid (PLGA), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and poly(H-caprolactone) or mixtures of two or more of the foregoing.
[0128] A therapeutic compounds / agents or other therapeutic agent(s) or mixtures thereof can be formulated in a carrier system. The carrier can be a colloidal system. The carrier or colloidal system can be a liposome, a phospholipid bilayer vehicle. In one embodiment, therapeutic compound(s) / agent(s) or other therapeutic agent(s) or mixtures thereof can be encapsulated in a liposome while maintaining integrity of the therapeutic compound(s) / agent(s) or other therapeutic agent(s) or mixtures thereof. One skilled in the art would appreciate that there are a variety of methods to prepare liposomes. (See Lichtenberg,et al., Methods Biochem. Anal., 33:337-462 (1988); Anselem, et al., Liposome Technology, CRC Press (1993)). Liposomal formulations can delay clearance and increase cellular uptake (See Reddy, Ann. Pharmacother., 34(7-8):915-923 (2000)). For example, an active agent can also be loaded into a particle prepared from pharmaceutically acceptable ingredients including, but not limited to, soluble, insoluble, permeable, impermeable, biodegradable or gastroretentive polymers or liposomes. Such particles include, but are not limited to, nanoparticles, biodegradable nanoparticles, microparticles, biodegradable microparticles, nanospheres, biodegradable nanospheres, microspheres, biodegradable microspheres, capsules, emulsions, liposomes, micelles and viral vector systems.
[0129] The carrier can also be a polymer, e.g., a biodegradable, biocompatible polymer matrix. In one embodiment, the therapeutic compound or other therapeutic agent or mixtures thereof can be embedded in the polymer matrix, while maintaining integrity of the composition. The polymer can be a microparticle or nanoparticle that encapsulates the therapeutic agent or agents. The polymer may be natural, such as polypeptides, proteins or polysaccharides, or synthetic, such as poly α-hydroxy acids. Examples include carriers made of, e.g., collagen, fibronectin, elastin, cellulose acetate, cellulose nitrate, polysaccharide, fibrin, gelatin, and combinations thereof. In one embodiment, the polymer is poly-lactic acid (PLA), poly lactic / glycolic acid (PLGA) or a mixture thereof. The polymeric matrices can be prepared and isolated in a variety of forms and sizes, including microspheres and nanospheres. Polymer formulations can lead to prolonged duration of therapeutic effect. (See Reddy, Ann. Pharmacother., 34(7-8):915-923 (2000)). A polymer formulation for human growth hormone (hGH) has been used in clinical trials. (See Kozarich and Rich, Chemical Biology, 2:548-552 (1998)).
[0130] Examples of polymer microsphere sustained release formulations are described in PCT publication WO 99 / 15154 (Tracy, et al.), U.S. Pat. Nos. 5,674,534 and 5,716,644 (both to Zale, et al.), PCT publication WO 96 / 40073 (Zale, et al.), and PCT publication WO 00 / 38651 (Shah, et al.). U.S. Pat. Nos. 5,674,534 and 5,716,644 and PCT publication WO 96 / 40073 describe a polymeric matrix containing particles of erythropoietin that are stabilized against aggregation with a salt.
[0131] In some embodiments, the nanoparticles or microparticles can be silica-based or silane-based (See for example: WO2002 / 080977 entitled: “Biodegradable carrier and method for preparation thereof”).
[0132] In some embodiments, the therapeutic compound(s) / agent(s) or other therapeutic agent(s) or mixtures thereof are prepared with carriers that will protect the therapeutic compound(s) / agent(s) or other therapeutic agent(s) or mixtures thereof against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using known techniques. The materials can also be obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to specific cells with monoclonal antibodies to cell-specific antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
[0133] The therapeutic compound(s) / agent(s) may be contained in controlled release systems. The term “controlled release” is intended to refer to any drug-containing formulation in which the manner and profile of drug release from the formulation are controlled. This refers to immediate as well as non-immediate release formulations, with non-immediate release formulations including but not limited to sustained release and delayed release formulations. The term “sustained release” (also referred to as “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period. The term “delayed release” is used in its conventional sense to refer to a drug formulation in which there is a time delay between administration of the formulation and the release of the drug therefrom to thereby make it available to the subject. “Delayed release” may or may not involve gradual release of drug over an extended period of time, and thus may or may not be “sustained release.”
[0134] Use of a long-term sustained release implant or depot formulation may be particularly suitable for treatment of chronic conditions. The term “implant” and “depot formulation” is intended to include a single composition (such as a mesh) or composition comprising multiple components (e.g. a fibrous mesh constructed from several individual pieces of mesh material) or a plurality of individual compositions where the plurality remains localized and provide the long-term sustained release occurring from the aggregate of the plurality of compositions. “Long-term” release, as used herein, means that the implant ordepot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 2 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 7 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 14 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 30 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 60 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient for at least 90 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least 180 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for at least one year. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for 15-30 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for 30-60 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for 60-90 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for 90-120 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for 120-180 days. In some embodiments, the implant or depot formulation is constructed and arranged to deliver therapeutic or prophylactic levels of the active ingredient(s) for up to one year. In some embodiments, the long-term sustained release implants or depot formulation are well-known to those of ordinary skill in the art and include some of the release systems described above. In some embodiments, such implants or depot formulation can be administered surgically. In some embodiments, such implants or depot formulation can be administered topically or by injection.III. Compounds & Compositions Useful In Practice Of The Methods, Uses & Medicaments Disclosed Herein
[0135] This disclosure provides compounds and compositions that are useful therapeutically and in investigational studies. In one aspect, the subject matter described herein relates to a type of bifunctional small molecule drug that triggers dephosphorylation of endogenous target proteins by recruiting an endogenously expressed phosphatase into close proximity. They consist of a Tau binder, a linker and a PP2A binder or activator. The molecules described recruit the ser / thr phosphatase PP2A to Tau found in dementia patient derived neurons, triggering selective targeted dephosphorylation at sites associated with disease, and triggering Tau protein clearance in patient derived iPSC-derived models of tauopathies. Compounds can be designed to target one, or multiple phosphor-sites by tuning the chemical structure. No molecules in this class for Tau have been described. Existing strategies for Tau dephosphorylation are based on kinase inhibition, which have failed in the clinic, or are restricted in terms of their effectiveness, due to the toxicity of inhibiting kinases that perform essential roles in cells beyond Tau phosphorylation. Bifunctional peptides that recruit PP1A to substrates have been described, but have not been broadly applied and are limited due to the non-drug like properties of peptides as compared to small molecules. Finally, recruitment of an exogenously expressed FKBP12-F36V tagged PP2A to a haloTagged exogenously expressed protein of interest have been described. However, since these systems rely on protein engineering of both the phosphatase and the target, they are unsuitable for use as therapeutics or for studying biology in patient-derived model systems as demonstrated here.
[0136] In one aspect, provided are compounds of Formula I, II, III, or IV:R1is H or alkyl; R2is H or alkyl; R3-R8are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R4and R5or R7and R8may join together to form a fused ring;L1is a linking group that is alkylene or a group of Formula AFormula A indicates the end that binds to Ar1; R34-R37are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R34and R35or R36and R37may join together to form a fused ring; L2is a linking group that is a group of Formula B, C, D, or E:where Ar2in Formula B, C, and D indicates the end that binds to Ar2; R30, R31, R38, R39, and R40are individually alkylenyl groups, polyethylene glycol groups, or polypropylene glycol groups; R32, R33, and R50are individually H or alkyl; R41-R44are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R41and R42or R43and R44may join together to form a fused ring;Ar2is a group of FormulaAr3is a group of FormulaR9is -CH2-, -CH2CH2-, -S-, or -O-; R10-R17are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R9-R16may join together to form a fused ring; L3is an alkylenyl group; R51-R57are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R51-R57may join together to form a fused ring; and R58is H, a group of formula -CH2NR59C(O)R60NR61Pr, or a group of formula -CH2NR59C(O)R60NR61Pr; R59and R61are individually H or alkyl; R60is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; Pr is H, alkyl, an amine protecting group, a group of formula -C(O)R62Ar1, or a group of Formula E; R62is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; R70is H, -C(O)OH, or -C(O)N(R59)R60NR61Pr; and R71is H, F, Cl, Br, or I.
[0137] In some embodiments the compound is of Formula I and each of R1and R32is individually H, methyl, or ethyl; each of R2-R8, R10-R15, R17, and R34-R37is H; and R16is F,Cl, or Br. In some embodiments the compound is of Formula I and L1is methylene, ethylene, propylene, or butylene. In some embodiments the compound is of Formula I and L1is a group of Formula A. In some embodiments the compound is of Formula I and R31is methylene, ethylene, propylene, or butylene; and R30is C4-C10alkylene, -(CH2CH2O)n- CH2CH2-, wherein n is 1 to 10. In some embodiments the compound is of Formula I and R9is -CH2CH2-. In some embodiments the compound is of Formula I, L2is of Formula C, and R38is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10. In some embodiments the compound is of Formula I, L2is of Formula B, and R30is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10. In some embodiments the compound is of Formula I, L2is of Formula D, and R40is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and each of R41-R44is H. In some embodiments the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or -(CH2CH2O)n- CH2CH2-; and Pr is H, methyl, a tert-butyloxycarbonyl (boc) group, or a group of formula - C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H. In some embodiments the compound is of Formula I, L2is of Formula B, R31is methylene, ethylene, propylene, or butylene; and R30is -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, R9is -CH2CH2-, and R16is Cl. In some embodiments the compound is of Formula I, L2is of Formula C, R38is -C4-C10alkylenyl-, -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, and R39is methylene, ethylene, propylene, or butylene. In some embodiments the compound is of Formula I, L1is methylene, ethylene, propylene, or butylene; R40is -C4-C10alkylenyl-, - (CH2CH2O)n-CH2CH2-, wherein n is 1 to 10. In some embodiments the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or - (CH2CH2O)n-CH2CH2- and n is 1 to 10; and Pr is a group of formula -C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H. In some embodiments the compound is of Formula III; R71is Cl, R70is -C(O)N(R59)R60NR61Pr, R59is H or methyl, R60is C4-C10alkylene or -(CH2CH2O)n-CH2CH2and n is 1 to 10, R61is H or methyl, and Pr is the group of formula -C(O)R62Ar1. In some embodiments the compound is any one or more of:.
[0138] Also provided are compositions comprising, or consisting essentially thereof, or consisting of a compound or a pharmaceutical acceptable salt thereof as disclosed herein, and a carrier, such as a pharmaceutically acceptable carrier. In another aspect, provided are pharmaceutical compositions comprising a compound or a pharmaceutical acceptable salt thereof as disclosed herein, and a carrier, such as a pharmaceutically acceptable carrier.
[0139] In one aspect, pharmaceutical compositions or compositions as disclosed herein comprising, or consisting essentially thereof, or consisting of, one or more pharmaceutically acceptable excipients.
[0140] Non-limiting examples of pharmaceutically acceptable carriers” include diluents, excipients, or carriers that can be used in the compositions disclosed herein. Pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. They may be selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
[0141] The compositions used in accordance with the disclosure can be packaged in dosage unit form for ease of administration and uniformity of dosage. The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the composition calculated to produce the desired responses in association with its administration, i.e., the appropriate route and regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the result and / or protection desired. Precise amounts of the composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the subject, route of administration, intended goal of treatment (alleviation of symptoms versus cure), and potency, stability, and toxicity of the particular composition. Upon formulation, solutions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described herein.Methods of Synthesis
[0142] Exemplary methods of synthesis for several of the compounds of the present disclosure are discussed in detail in the Examples section. In some embodiments, the compounds of the present disclosure were synthesized according to the following scheme:
[0143] In some embodiments, the compounds of the present disclosure were synthesized according to the following scheme:
[0144] In some embodiments, the compounds of the present disclosure were synthesized according to the following scheme:
[0145] In some embodiments, the compounds of the present disclosure were synthesized according to the following scheme:
[0146] In some embodiments, the compounds of the present disclosure were synthesized according to the following scheme:IV. Therapeutic Methods And Related Uses Therapeutic Methods
[0147] In some embodiments, this application pertains to a method for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, the compound of the present disclosure is JWJ-1-002, JWJ-1-008, JWJ-1-099, JWJ-1-116, JWJ-1-102, JWJ-1-115, JWJ-1-096, JWJ-1- 122, JWJ-1-123, JWJ-1-027, JWJ-1-085, JWJ-1-010, JWJ-1-028, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, said administration of the compound of the present disclosure may reduce Tau species levels, and in particular reduce phosphorylated Tau (e.g. P-Tau AT8). In some embodiments, said administration of the compound of the present disclosure may reduce the toxicity associated with cellular Tau accumulation. In some embodiments, said administration of the compound of the present disclosure may reduce cellular oxidative stress caused by cellular accumulation of Tau protein.
[0148] In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism–dementia complex, anti-IgLON5-related tauopathy, Caribbean Parkinsonism, chronic traumatic encephalopathy, diffuse neurofibrillary tangles with calcification, progressive supranuclear palsy, Down syndrome, Familial British dementia, Familial Danish dementia, Niemann-Pick disease type C, non- Guamanian motor neuron disease with neurofibrillary tangles, postencephalitic Parkinsonism, primary age-related tauopathy, progressive ataxia, palatal tremor, neurofibrillary dementia, familial frontotemporal dementia, Parkinsonism, Pick's disease, argyrophilic grain disease, corticobasal degeneration, Guadeloupean Parkinsonism, globular glial tauopathy, Huntington's Disease, SLC9a-related Parkinsonism, or aging-related Tau astrogliopathy. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is Alzheimer’s disease. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is Pick’s disease. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is corticobasal degeneration. In some embodiments, the tauopathyto be addressed by the administration of the compound of the present disclosure is progressive supranuclear palsy. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is global glial tauopathy. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is argyrophilic grain disease. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is familial British dementia. In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is familial Danish dementia.
[0149] In some embodiments, the tauopathy to be addressed by the administration of the compound of the present disclosure is primary age-related tauopathy. For example, the primary age-related tauopathy can be selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy.
[0150] According to the above disclosed methods, in some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 2 weeks or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 12 weeks or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 24 weeks or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 48 weeks or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 1 year or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for2 years or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 5 years or more. In some embodiments, the compound of the present disclosure is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 1 year or more. In some embodiments, the compound of the present disclosure is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the compound is no longer effective.
[0151] It will be appreciated that the frequency with which any of these compounds of the present disclosure can be administered can be once or more than once over a period of about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 20 days, about 28 days, about a week, about 2 weeks, about 3 weeks, about 4 weeks, about a month, about every 2 months, about every 3 months, about every 4 months, about every 5 months, about every 6 months, about every 7 months, about every 8 months, about every 9 months, about every 10 months, about every 11 months, about every year, about every 2 years, about every 3 years, about every 4 years, or about every 5 years.
[0152] For example, the compositions and compounds of the present disclosure may be administered daily, weekly, biweekly, or monthly for a particular period of time. The compositions and compounds of the present disclosure may be dosed daily over a 14 day time period, or twice daily over a seven day time period. The compositions and compounds of the present disclosure may be administered daily for 7 days.
[0153] Alternatively, the compositions and compounds of the present disclosure may be administered daily, weekly, biweekly, or monthly for a particular period of time followed by a particular period of non-treatment. In some embodiments, the compositions and compounds of the present disclosure can be administered daily for 14 days followed by seven days of non-treatment, and repeated for two more cycles of daily administration for 14 days followed by seven days of non-treatment. In some embodiments, the compositions and compounds of the present disclosure can be administered twice daily for seven days followed by 14 days of non-treatment, which may be repeated for one or two more cycles of twice daily administration for seven days followed by 14 days of non-treatment.
[0154] In some embodiments, the compositions and compounds of the present disclosure are administered daily over a period of 14 days. In another embodiment, the compositions and compounds of the present disclosure are administered daily over a period of 12 days, or 11 days, or 10 days, or nine days, or eight days. In another embodiment, the compositions and compounds of the present disclosure are administered daily over a period of seven days. In another embodiment, the compositions and compounds of the present disclosure are administered daily over a period of six days, or five days, or four days, or three days.
[0155] According to the above disclosed methods, in some embodiments, the subject is a mammal. In some embodiments, the subject is human.
[0156] According to the above disclosed methods, in some embodiments, the compounds of the present disclosure are administered orally. In some embodiments, the compounds of the present disclosure are administered subcutaneously. In some embodiments, the compounds of the present disclosure are administered topically. In some embodiments, the compounds of the present disclosure are administered intranasally. In some embodiments, the compounds of the present disclosure are administered systemically. In some embodiments, the compounds of the present disclosure are administered intravenously. In some embodiments, the compounds of the present disclosure are administered intraperitoneally. In some embodiments, the compounds of the present disclosure are administered intradermally. In some embodiments, the compounds of the present disclosure are administered intraocularly. In some embodiments, the compounds of the present disclosure are administered ophthalmically. In some embodiments, the compounds of the present disclosure are administered intrathecally. In some embodiments, the compounds of the present disclosure are administered intracerebroventricularly. In some embodiments, the compounds of the present disclosure are administered iontophoretically. In some embodiments, the compounds of the present disclosure are administered transmucosally. In some embodiments, the compounds of the present disclosure are administered intravitreally. In some embodiments, the compounds of the present disclosure are administered intramuscularly. In some embodiments, the compounds the compounds of the present disclosure are administered to directly to the central nervous system, for example via intrathecal administration, intracerebroventricular administration, or wafer insertion.
[0157] According to the above disclosed methods, in some embodiments, the small molecule peptide is administered in the form of a pharmaceutically acceptable salt.Therapeutic Uses Related to Compositions & Medicaments:
[0158] In some embodiments, this application pertains to therapeutic uses of the compounds disclosed herein as formulated into compositions and / or medicaments suitable for administration to a subject for the purpose of treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition / medicament comprises a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. Thus, in some embodiments, this application pertains to the use of a composition in the preparation of a medicament for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, the compound of the present disclosure suitable for said use is JWJ-1-002, JWJ-1-008, JWJ-1-099, JWJ-1-116, JWJ-1-102, JWJ-1-115, JWJ-1- 096, JWJ-1-122, JWJ-1-123, JWJ-1-027, JWJ-1-085, JWJ-1-010, JWJ-1-028, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof. In some embodiments, said use of the composition / medicament may reduce Tau species levels in the subject, and in particular reduce phosphorylated Tau (e.g. P-Tau AT8). In some embodiments, said use of the composition / medicament may reduce the toxicity associated with cellular Tau accumulation in the subject. In some embodiments, said use of the composition / medicament may reduce cellular oxidative stress caused by cellular accumulation of Tau protein in the subject.
[0159] In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism–dementia complex, anti-IgLON5-related tauopathy, Caribbean Parkinsonism, chronic traumatic encephalopathy, diffuse neurofibrillary tangles with calcification, progressive supranuclear palsy, Down syndrome, Familial British dementia, Familial Danish dementia, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, postencephalitic Parkinsonism, primary age-related tauopathy, progressive ataxia, palatal tremor, neurofibrillary dementia, familial frontotemporal dementia, Parkinsonism, Pick's disease, argyrophilic grain disease, corticobasal degeneration, Guadeloupean Parkinsonism, globular glial tauopathy, Huntington's Disease, SLC9a-related Parkinsonism, or aging-relatedTau astrogliopathy. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is Alzheimer’s disease. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is Pick’s disease. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is corticobasal degeneration. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is progressive supranuclear palsy. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is global glial tauopathy. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is argyrophilic grain disease. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is familial British dementia. In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is familial Danish dementia.
[0160] In some embodiments, the tauopathy to be addressed by use of the composition / medicament comprising the compound of the present disclosure is primary age- related tauopathy. For example, the primary age-related tauopathy can be selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy.
[0161] According to the above disclosed uses, in some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 2 weeks or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 12 weeks or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 24 weeks or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 48 weeks or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 1 year or more. In some embodiments, the composition / medicament comprising the compound of the presentdisclosure is administered daily for 2 years or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 5 years or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered daily for 1 year or more. In some embodiments, the composition / medicament comprising the compound of the present disclosure is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the compound is no longer effective.
[0162] It will be appreciated that the frequency with which the composition / medicament comprising the compound of the present disclosure of the present disclosure can be administered can be once or more than once over a period of about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 20 days, about 28 days, about a week, about 2 weeks, about 3 weeks, about 4 weeks, about a month, about every 2 months, about every 3 months, about every 4 months, about every 5 months, about every 6 months, about every 7 months, about every 8 months, about every 9 months, about every 10 months, about every 11 months, about every year, about every 2 years, about every 3 years, about every 4 years, or about every 5 years.
[0163] For example, the composition / medicament comprising the compound of the present disclosure may be administered daily, weekly, biweekly, or monthly for a particular period of time. The composition / medicament comprising the compound of the present disclosure may be dosed daily over a 14 day time period, or twice daily over a seven day time period. The composition / medicament comprising the compound of the present disclosure may be administered daily for 7 days.
[0164] Alternatively, the composition / medicament comprising the compound of the present disclosure may be administered daily, weekly, biweekly, or monthly for a particular period of time followed by a particular period of non-treatment. In some embodiments, the composition / medicament comprising the compound of the present disclosure can be administered daily for 14 days followed by seven days of non-treatment, and repeated for two more cycles of daily administration for 14 days followed by seven days of non-treatment. In some embodiments, the composition / medicament comprising the compound of the present disclosure can be administered twice daily for seven days followed by 14 days of non-treatment, which may be repeated for one or two more cycles of twice daily administration for seven days followed by 14 days of non-treatment.
[0165] In some embodiments, the composition / medicament comprising the compound of the present disclosure are administered daily over a period of 14 days. In another embodiment, the composition / medicament comprising the compound of the present disclosure are administered daily over a period of 12 days, or 11 days, or 10 days, or nine days, or eight days. In another embodiment, the composition / medicament comprising the compound of the present disclosure are administered daily over a period of seven days. In another embodiment, the composition / medicament comprising the compound of the present disclosure are administered daily over a period of six days, or five days, or four days, or three days.
[0166] According to the above disclosed uses, in some embodiments, the subject is a mammal. In some embodiments of the above disclosed uses, the subject is human.
[0167] According to the above disclosed uses, in some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for oral administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for subcutaneous administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for topical administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intranasal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for systemic administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intravenous administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intraperitoneal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intradermal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intraocular administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for ophthalmic administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulatedfor intrathecal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intracerebroventricular administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for iontophoretical administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for transmucosal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intravitreal administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for intramuscular administration. In some embodiments, the composition / medicament comprising the compound of the present disclosure is formulated for direct administration to the central nervous system, for example via intrathecal administration, intracerebroventricular administration, or wafer insertion.
[0168] According to the above disclosed uses, in some embodiments, the compound of the present disclosure used in formulating the composition / medicament is a pharmaceutically acceptable salt.
[0169] The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention. Therapeutic Uses Related to Combinatorial Compositions & Medicaments:
[0170] It is envisioned that any of the compositions, medicaments, and methods disclosed herein may comprise a combination of one or more compounds of the present disclosure with a known therapeutic for tauopathies. The compounds can be administered in combination with one or more additional therapeutic compounds / agents (a so called “co-administration” where, for example, the additional therapeutic agent could be administered simultaneously, sequentially or by separate administration using either the same route or a different route of administration than the compound of the present disclosure). The one or more additional therapeutic agents could be, for example, a small molecule therapeutic agent selected from the group consisting of: an activator / modulator of Tau phosphorylation, a kinase inhibitor, a modulator of Tau acylation, a histone deacetylase (HDAC) inhibitor, a modulator / inhibitor of Tau glycosylation (e.g. an O-GlcNAcase inhibitor), a modulator of Tau truncation (e.g. a capsase inhibitor), a Tau aggregation / fibrillization inhibitor, a proteasome stimulator, aUSP14 inhibitor, a phosphodiesterase inhibitor, a proteolysis targeting chimera (PROTAC), a autophagy activator, a Hsp70 modulator, a Hsp90 modulator, a co-chaperone modulator and a Tau oriented multi-target directed ligand (See the review article: Wang, L., et al. “Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking the path of most resistance”, European Journal of Medicinal Chemistry, 209 (2021) 112915).
[0171] In some embodiments, the one or more additional therapeutic agent comprises an antagonist of the N-methyl-D-aspartate receptor (e.g., mematine), an antibody against amyloid beta (e.g., lecanemab), an acetylcholinesterase inhibitor (e.g., pyridostigmine, neostigmine, galantamine, and ambenonium), and / or kinase inhibitors (e.g. lithium), wherein kinase inhibitors can target, for example, serine / threonine kinases, tyrosine kinases, PI3K, mTOR, or a combination thereof. It is anticipated that the combination of one or more additional therapeutic agent with the compounds of the present technology will result in synergistic improvements to therapeutic outcomes when administered to subjects.
[0172] Thus, in some embodiments, this application anticipates that one or more compounds of the present technology in combination with modulators of Tau phosphorylation, kinase inhibitors, modulators of Tau acylation, histone deacetylase (HDAC) inhibitors, modulators / inhibitors of Tau glycosylation, modulators of Tau truncation, Tau aggregation inhibitors, proteasome stimulators, USP14 inhibitors, phosphodiesterase inhibitors and PROTACs, autophagy activators, chaperone modulators, co-chaperone modulators, Tau oriented multi-target directed ligands, antagonists of the N-methyl-D- aspartate receptor (e.g., mematine), antibodies against amyloid beta (e.g., lecanemab), acetylcholinesterase inhibitors (e.g., pyridostigmine, neostigmine, galantamine, and ambenonium), and / or kinase inhibitors (e.g. lithium) can be co-administered to a subject, each in an effective amount, to treat, prevent, inhibit, ameliorate or delay the onset of a tauopathy. Such co-administration can be by simultaneous or sequential administration. Such co-administration can be by the same formulation or by different formulations. Such co-administration can be by the same route or administration or by different routes of administration. In some embodiments, the combination of a compound of the present disclosure and an additional therapeutic treatment / agent has a synergistic effect in the treatment of the tauopathy. EXAMPLES
[0173] Synthesis.
[0174] A series of small molecules comprising a phosphatase (PP2A) binder and a Tau binder connected by a linker. Molecules were generated using a version of the HATU coupling reaction and were then assessed via NMR, mass spectrometry and HPLC.
[0175] All chemicals and solvents were purchased from commercial suppliers and directly used without further purification unless otherwise specified. The following chemical intermediates were provided by the Dana Farber Cancer Institute: FMF-01-117 (tert-butyl (7- ((4-(N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5- yl)propyl)sulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate), FMF-01-118 (tert-butyl (7-((4- (N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-N- methylsulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate), FMF-01-119 (tert-butyl (2-(2-(2- (3-((4-(N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5- yl)propyl)sulfamoyl)phenyl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)carbamate), FMF- 01-120 (tert-butyl (2-(2-(2-(3-((4-(N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5- yl)propyl)-N-methylsulfamoyl)phenyl)amino)-3- oxopropoxy)ethoxy)ethoxy)ethyl)carbamate), FMF-06-121 ((2-chloro-10H-phenothiazin-10- yl)(4-methoxyphenyl)methanone), FMF-01-122 (tert-butyl (6-(4-(2-chloro-10H- phenothiazine-10-carbonyl)phenoxy)hexyl)carbamate), FMF-01-123 (tert-butyl (2-(2-(2-(2- (4-(2-chloro-10H-phenothiazine-10- carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate), FMF-06-124 (2-(4-(3-(2-chloro- 10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethan-1-ol), FMF-01-125 (tert-butyl (6-(4-(3- (2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)hexyl)carbamate), and FMF-01-126 (tert-butyl (2-(2-(2-(2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1- yl)ethoxy)ethoxy)ethoxy)ethyl)carbamate). Reactions were monitored by either Waters Acquity UPLC system or TLC on 0.2 mm silica gel plates (Merck Kieselgel GF254) and visualized under UV light (254 nm). For the intermediates, preparatory-scale flash column chromatography was conducted using medium-pressure liquid chromatography (MPLC) on a CombiFlash® Companion (Teledyne ISCO) with pre-packed silica columns (20–40 microns) and UV detection at 254 nm. For all the final compounds, preparative HPLC was performed on a Waters Sunfire C18 column (19 mm × 50 mm, 5 μM) using a gradient of 15−95% methanol in water containing 0.05% trifluoroacetic acid (TFA) over either 28 or 45 min run time at a flow rate of 20 mL / min.1H NMR spectra were recorded on 500 MHz JEOL ECA 500 spectrometer, and chemical shifts are reported in parts per million (ppm, δ). Couplingconstants (J) are reported in Hz. Spin multiplicities are described as s (singlet), br (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Mass spectra were obtained on a Waters Acquity UPLC. Final compounds were isolated and tested as TFA salts. Purities of assayed compounds were in all cases greater than 95%, as determined by reverse-phase HPLC analysis.
[0176] General HATU Coupling Procedure: Corresponding PP2A binder with varying Boc protected liner (1 equiv) was treated with a 1:1 (v / v) mixture of DCM / TFA (5 mL / mmol) for 30 min. Upon the completion of the removal of the Boc group indicated by UPLC, excess TFA and DCM were evaporated under reduced pressure. After putting on the high vacuum for additional 2 hours to fully remove TFA, the residue was dissolved in DMF (1 mL). HATU (1.5 equiv), DIPEA (2 equiv), and the corresponding acid (1 equiv) were added to the solution and stirred overnight. Upon the completion of the HATU coupling indicated by UPLC, the mixture was diluted with DMSO to 5 mL and filtered through a 13 mm syringe filter (0.45 um, PTFE). The resulting filtrate was loaded and purified via the preparative HPLC, which yielded the desired compound as a TFA salt.
[0177] Example 1. Synthesis of 7-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-(4-(N- (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin- 5- yl)propyl)sulfamoyl)phenyl)heptanamide (JWJ-01-002).
[0178] The title compound was generated via the general procedure of HATU coupling using FMF-01-117-1 (tert-butyl (7-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate,56 mg,0.083 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (7.4 mg, 9.5%) with 97% purity.1H NMR (500 MHz, DMSO-d6) δ 12.99 (s, 1H), 10.19 (s, 1H), 9.64 (s, 1H), 8.58 (d, J = 6.7 Hz, 1H), 8.29 (d, J = 8.1 Hz, 1H),7.93 (d, J = 6.7 Hz, 1H), 7.79 (t, J = 5.6 Hz, 1H), 7.66 (d, J = 8.6 Hz, 2H), 7.58–7.53 (m, 3H), 7.39 (t, J = 5.7 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 7.13–7.03 (m, 2H), 7.03–6.98 (m, 3H), 6.96–6.84 (m, 2H), 3.59 (t, J = 6.6 Hz, 2H), 2.99 (p, J = 7.3, 6.6 Hz, 4H), 2.91 (s, 4H), 2.70 (q, J = 6.6 Hz, 2H), 2.52–2.40 (m, 2H), 2.26 (t, J = 7.4 Hz, 2H), 1.47 (p, J = 7.2 Hz, 4H), 1.31 (q, J =7.2 Hz, 2H), 1.18 (s, 4H). MS (ESI) m / z 791 (M + H)+.
[0179] Example 2. Synthesis of 7-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-(4-(N- (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin- 5-yl)propyl)-N- methylsulfamoyl)phenyl)heptanamide (JWJ-01-006).
[0180] The title compound was generated via the general procedure of HATU coupling using FMF-01-118-1 (tert-butyl (7-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate, 57 mg, 0.083 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (4.9 mg, 6.3%) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 12.96 (s, 1H), 10.23 (s, 1H), 9.63 (s, 1H), 8.57 (s, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.78 (t, J = 5.6 Hz, 1H), 7.75–7.69 (m, 2H), 7.58–7.49 (m, 3H), 7.31 (dd, J = 8.0, 1.4 Hz, 1H), 7.12 (dd, J = 8.0, 6.2 Hz, 2H), 7.09–7.03 (m, 3H), 6.97–6.87 (m, 2H), 3.64 (t, J = 6.5 Hz, 2H), 3.07–2.94 (m, 8H), 2.91 (t, J = 7.2 Hz, 2H), 2.50 (s, 3H), 2.43 (t, J = 7.6 Hz, 2H), 2.25 (t, J = 7.4 Hz, 2H), 1.56 (p, J = 6.6 Hz, 2H), 1.46 (p, J = 7.4 Hz, 2H), 1.30 (p, J = 7.0 Hz, 2H), 1.21–1.11 (m, 4H). MS (ESI) m / z 805 (M + H)+.
[0181] Example 3. Synthesis of 3-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethoxy)-N-(4-(N-(3-(3-chloro-10,11- dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)propenamide (JWJ-01-007).
[0182] The title compound was generated via the general procedure of HATU coupling using FMF-01-119-1 (tert-butyl (2-(2-(2-(3-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)amino)-3- oxopropoxy)ethoxy)ethoxy)ethyl)carbamate, 63 mg, 0.083 mmol) and 3-(5H-pyrido[4,3- b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (4.2 mg, 4.9%) with 95% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 10.30 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.99–7.88 (m, 2H), 7.73–7.67 (m, 2H), 7.61–7.56 (m, 3H), 7.43 (t, J = 5.7 Hz, 1H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 7.14–7.08 (m, 2H), 7.04 (dd, J = 5.3, 2.9 Hz, 3H), 6.97–6.87 (m, 2H), 3.70 (t, J = 6.2 Hz, 2H), 3.65– 3.60 (m, 4H), 3.43–3.38 (m, 6H), 3.33 (t, J = 5.9 Hz, 2H), 3.16 (q, J = 5.8 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.94 (s, 4H), 2.73 (q, J = 6.6 Hz, 2H), 2.59 (t, J = 6.1 Hz, 2H), 2.47 (d, J = 7.7 Hz, 2H), 1.50 (p, J = 6.7 Hz, 2H). MS (ESI) m / z 867 (M + H)+.
[0183] Example 4. Synthesis of 3-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethoxy)-N-(4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)propenamide (JWJ-01-008).
[0184] The title compound was generated via the general procedure of HATU coupling using FMF-01-120-1 (tert-butyl (2-(2-(2-(3-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)carbamate, 80 mg, 0.10 mmol) and 3-(5H-pyrido[4,3- b]indol-7-yl)propanoic acid (25 mg, 0.10 mmol), which yielded a while solid (15.1 mg, 15%) with 99% purity.1H NMR (599 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 6.7 Hz, 1H), 7.92 (t, J = 5.7 Hz, 1H), 7.75 (d, J = 8.8 Hz, 2H), 7.59 (s, 1H), 7.57–7.53 (m, 2H), 7.34 (dd, J = 8.1, 1.4 Hz, 1H), 7.14 (d, J = 7.3 Hz, 2H), 7.09 (dd, J =5.2, 3.0 Hz, 3H), 6.97 (td, J = 7.3, 1.3 Hz, 1H), 6.93 (dd, J = 8.1, 2.1 Hz, 1H), 3.69 (t, J = 6.2 Hz, 2H), 3.67 (t, J = 6.5 Hz, 3H), 3.56 (s, 2H), 3.49 (s, 2H), 3.40 (dd, J = 6.4, 3.9 Hz, 4H), 3.32 (d, J = 5.8 Hz, 2H), 3.18–3.15 (m, 2H), 3.05 (dd, J = 9.5, 4.4 Hz, 6H), 2.95 (t, J = 7.2 Hz, 2H), 2.59 (t, J = 6.2 Hz, 2H), 2.53 (s, 3H),2.48 (d, J = 7.7 Hz, 2H), 1.59 (p, J = 6.7 Hz, 2H). MS (ESI) m / z 881 (M + H)+.
[0185] Example 5. Synthesis of 7-(2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetamido)-N-(4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5- yl)propyl)sulfamoyl)phenyl)heptanamide (JWJ-01-056).
[0186] The title compound was generated via the general procedure of HATU coupling using FMF-01-117-1 (tert-butyl (7-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate, 44 mg, 0.063 mmol) and 2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2-yl)oxy)acetic acid (25 mg, 0.078 mmol), which yielded a while solid (3.0 mg, 3.8%) with 98% purity. 1H NMR (599 MHz, DMSO-d6) δ 10.20 (s, 1H), 9.72 (s, 1H),8.65 (s, 1H), 8.59 (d, J = 2.6 Hz, 1H), 8.49 (d, J = 8.2 Hz, 1H), 8.21 (dd, J = 8.6, 2.6 Hz, 1H), 8.03 (t, J =5.8 Hz, 1H), 8.00 (s, 1H), 7.98 (s, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.40 (t, J = 5.7 Hz, 1H), 7.13–7.06 (m, 3H), 7.03 (dd, J = 5.5, 2.9 Hz, 3H), 6.96–6.87 (m, 2H), 6.55 (s, 1H), 4.78 (s, 2H), 3.62 (t, J = 6.6 Hz, 2H), 3.11 (q, J = 6.6 Hz, 2H), 2.94 (s, 4H), 2.72 (q, J = 6.6 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.58 (p, J = 7.3 Hz, 2H), 1.47 (dp, J = 39.5, 6.9 Hz, 4H), 1.29 (qd, J = 12.2, 10.4, 4.2 Hz, 4H). MS (ESI) m / z 870 (M + H)+.
[0187] Example 6. Synthesis of 3-(2-(2-(2-(2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetamido)ethoxy)ethoxy)ethoxy)-N-(4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)propenamide (JWJ-01-052).
[0188] The title compound was generated via the general procedure of HATU coupling using FMF-01-119-1 (tert-butyl (2-(2-(2-(3-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)sulfamoyl)phenyl)amino)-3- oxopropoxy)ethoxy)ethoxy)ethyl)carbamate, 48 mg, 0.063 mmol) and 2-((5-(5H-pyrido[4,3- b]indol-7-yl)pyridin-2-yl)oxy)acetic acid (25 mg, 0.078 mmol), which yielded a while solid (3.8 mg, 4.5%) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.13 (s, 1H), 10.27 (s, 1H), 9.73 (s, 1H), 8.63 (s, 1H), 8.56 (d, J = 2.5 Hz, 1H), 8.48 (d, J = 8.2 Hz, 1H), 8.17 (dd, J = 8.7, 2.6 Hz, 1H), 8.06 (t, J = 5.8 Hz, 1H), 7.97 (t, J = 2.9 Hz, 2H), 7.77 (dd, J = 8.3, 1.6 Hz, 1H), 7.69–7.63 (m, 2H), 7.58–7.52 (m, 2H), 7.39 (t, J = 5.7 Hz, 1H), 7.10–7.00 (m, 3H), 7.00 (dd, J = 5.3, 2.9 Hz, 3H), 6.93–6.83 (m, 2H), 4.76 (s, 2H), 3.67 (t, J = 6.2 Hz, 2H), 3.58 (t, J = 6.5 Hz, 2H), 3.45 (dtd, J = 16.1, 4.4, 2.6 Hz, 8H), 3.38 (t, J = 5.9 Hz, 2H), 3.22 (q, J = 5.9 Hz, 2H), 2.90 (s, 4H), 2.69 (q, J = 6.6 Hz, 2H), 2.56 (t, J = 6.2 Hz, 2H), 1.47 (p, J = 6.7 Hz, 2H). MS (ESI) m / z 946 (M + H)+.
[0189] Example 7. Synthesis of 7-(2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetamido)-N-(4-(N-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)- N-methylsulfamoyl)phenyl)heptanamide (JWJ-01-057).
[0190] The title compound was generated via the general procedure of HATU coupling using FMF-01-118-1 (tert-butyl (7-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)amino)-7-oxoheptyl)carbamate, 44 mg, 0.063 mmol) and 2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2-yl)oxy)acetic acid (25 mg, 0.078 mmol), which yielded a while solid (2.1 mg, 2.6 %) with 96% purity. 1H NMR (599 MHz, DMSO-d6) δ 10.24 (s, 1H), 9.73 (s, 1H), 8.65 (s, 1H), 8.59 (s, 1H), 8.50 (d, J = 8.1 Hz, 1H), 8.21 (dd, J = 8.7, 2.7 Hz, 1H), 8.03 (t, J = 5.8 Hz, 1H), 7.99 (d, J = 4.7 Hz, 2H), 7.79 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.4 Hz, 2H), 7.11–7.05 (m, 5H), 7.00–6.90 (m, 2H), 6.55 (s, 1H), 4.78 (d, J = 5.2 Hz, 2H), 3.66 (t, J =6.6 Hz, 2H), 3.11 (q, J = 6.6 Hz, 2H), 3.04 (p, J = 5.5, 4.4 Hz, 4H), 2.94 (t, J = 7.3 Hz, 3H), 2.50 (t, J = 2.9 Hz, 3H), 2.32 (t, J = 7.4 Hz, 2H), 1.60–1.57 (m, 4H), 1.43 (p, J = 7.1 Hz, 2H), 1.31–1.25 (m, 4H). MS (ESI) m / z 884 (M + H)+.
[0191] Example 8. Synthesis of 3-(2-(2-(2-(2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetamido)ethoxy)ethoxy)ethoxy)-N-(4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)propenamide (JWJ- 01-097).
[0192] The title compound was generated via the general procedure of HATU coupling using FMF-01-120-1 (tert-butyl (2-(2-(2-(3-((4-(N-(3-(3-chloro-10,11-dihydro-5H- dibenzo[b,f]azepin-5-yl)propyl)-N-methylsulfamoyl)phenyl)amino)-3- oxopropoxy)ethoxy)ethoxy)ethyl)carbamate, 32 mg, 0.042 mmol) and 2-((5-(5H-pyrido[4,3- b]indol-7-yl)pyridin-2-yl)oxy)acetic acid (15 mg, 0.047 mmol), which yielded a while solid (9.6 mg, 19 %) with 99% purity. 1H NMR (500 MHz, DMSO-d6) δ 13.19 (s, 1H), 10.35 (s, 1H), 9.77 (s, 1H), 8.67 (d, J = 6.7 Hz, 1H), 8.60 (d, J = 2.6 Hz, 1H), 8.52 (d, J = 8.3 Hz, 1H), 8.21 (dd, J = 8.6, 2.6 Hz, 1H), 8.10 (t, J = 5.7 Hz, 1H), 8.01 (dd, J = 4.2, 2.6 Hz, 2H), 7.80 (dd, J = 8.3, 1.6 Hz, 1H), 7.79–7.72 (m, 2H), 7.60–7.51 (m, 2H), 7.18–7.08 (m, 3H), 7.11– 7.04 (m, 3H), 7.00–6.90 (m, 2H), 4.80 (s, 2H), 3.68 (dt, J = 15.9, 6.4 Hz, 4H), 3.48 (ddt, J = 12.2, 4.6, 2.2 Hz, 8H), 3.41 (t, J = 5.9 Hz, 2H), 3.25 (q, J = 5.8 Hz, 2H), 3.09–2.99 (m, 4H), 2.94 (t, J = 7.2 Hz, 2H), 2.58 (t, J = 6.2 Hz, 2H), 2.52 (s, 3H), 1.58 (p, J = 6.8 Hz, 2H). MS (ESI) m / z 960 (M + H)+.
[0193] Example 9. Synthesis of N-(6-(4-(3-(2-chloro-10H-phenothiazin-10- yl)propyl)piperazin-1-yl)hexyl)-3-(5H-pyrido[4,3-b]indol-7- yl)propenamide (JWJ-01-027).
[0194] The title compound was generated via the general procedure of HATU coupling using FMF-01-125-1 (tert-butyl (6-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin- 1-yl)hexyl)carbamate, 48 mg, 0.083 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (2.6 mg, 3.9 %) with 99% purity. 1H NMR (500 MHz, DMSO-d6) δ 13.10 (s, 1H), 9.69 (s, 1H), 8.63 (d, J =6.7 Hz, 1H), 8.33 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 6.7 Hz, 1H), 7.86 (t, J = 5.6 Hz, 1H), 7.59 (s, 1H), 7.35 (dd, J = 8.2, 1.4 Hz, 1H), 7.24 (ddd, J = 8.5, 7.4, 1.6 Hz, 1H), 7.22–7.17 (m, 2H), 7.13–7.06 (m, 2H), 7.05–6.97 (m, 2H), 3.96 (t, J = 6.9 Hz, 9H), 3.02 (dt, J = 9.8, 7.0 Hz, 10H), 2.47 (dd, J = 8.6, 6.9 Hz, 1H), 1.97 (s, 2H), 1.54 (s, 2H), 1.36 (d, J = 7.0 Hz, 2H), 1.28–1.18 (m, 4H). MS (ESI) m / z 681 (M + H)+.
[0195] Example 10. Synthesis of N-(2-(2-(2-(2-(4-(3-(2-chloro-10H-phenothiazin-10- yl)propyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-3- (5H-pyrido[4,3-b]indol-7- yl)propenamide (JWJ-01-085).
[0196] The title compound was generated via the general procedure of HATU coupling using FMF-01-126-1 (tert-butyl (2-(2-(2-(2-(4-(3-(2-chloro-10H-phenothiazin-10- yl)propyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)carbamate, 43 mg, 0.067 mmol) and 3- (5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (4.4 mg, 3.9 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.10 (s, 1H), 9.68 (s, 1H), 8.63 (d, J =6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.01–7.92 (m, 2H), 7.59 (s, 1H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 7.27–7.22 (m, 1H), 7.20–7.16 (m, 2H), 7.11 (d, J = 2.1 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.04–6.98 (m, 2H), 3.95 (t, J = 6.9 Hz, 8H), 3.67 (t, J = 5.0 Hz, 3H), 3.53 (dd, J = 6.3, 3.3 Hz, 2H), 3.50 (dd, J = 5.7, 2.9 Hz, 2H), 3.46 (q, J = 1.7 Hz, 4H), 3.36 (t, J = 6.0 Hz, 3H), 3.19 (q, J = 6.0 Hz, 4H), 3.03 (t, J = 7.7 Hz, 4H), 2.48 (d, J = 7.4 Hz, 2H), 1.98 (s, 2H). MS (ESI) m / z 757 (M + H)+.
[0197] Example 11. Synthesis of N-(6-(4-(2-chloro-10H-phenothiazine-10- carbonyl)phenoxy)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propenamide (JWJ-01-010).
[0198] The title compound was generated via the general procedure of HATU coupling using FMF-01-122-1 (tert-butyl (6-(4-(2-chloro-10H-phenothiazine-10- carbonyl)phenoxy)hexyl)carbamate, 59 mg, 0.10 mmol) and 3-(5H-pyrido[4,3-b]indol-7- yl)propanoic acid (25 mg, 0.10 mmol), which yielded a while solid (4.5 mg, 3.9 %) with 99%purity. 1H NMR (500 MHz, DMSO-d6) δ 12.93 (s, 1H), 9.62 (s, 1H), 8.56 (s, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.76 (t, J = 5.6 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H), 7.60–7.51 (m, 3H), 7.36–7.25 (m, 3H), 7.25–7.15 (m, 4H), 6.79–6.73 (m, 2H), 3.80 (t, J = 6.5 Hz, 2H), 2.98 (dt, J = 18.4, 7.0Hz, 4H), 2.43 (t, J = 7.6 Hz, 2H), 1.49 (p, J = 6.6 Hz, 2H), 1.24 (dq, J = 28.6, 6.9, 6.4 Hz, 4H), 1.12 (q, J = 7.9 Hz, 2H). MS (ESI) m / z 675 (M + H)+.
[0199] Example 12. Synthesis of N-(2-(2-(2-(2-(4-(2-chloro-10H-phenothiazine-10- carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propenamide (JWJ-01-089).
[0200] The title compound was generated via the general procedure of HATU coupling using FMF-01-123-1 (tert-butyl (2-(2-(2-(2-(4-(2-chloro-10H-phenothiazine-10- carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)carbamate, 42 mg, 0.067 mmol) and 3-(5H- pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), which yielded a while solid (7.2 mg, 9.5 %) with 95% purity. 1H NMR (500 MHz, DMSO-d6) δ 13.01 (s, 1H), 9.67 (s, 1H), 8.62 (d, J =6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.95 (dd, J = 14.6, 6.2 Hz, 2H), 7.70 (d, J = 2.2 Hz, 1H), 7.61–7.55 (m, 3H), 7.38–7.33 (m, 2H), 7.30 (dd, J = 7.6, 1.7 Hz, 1H), 7.27–7.18 (m, 4H), 6.85–6.80 (m, 2H), 4.07 –4.02 (m, 2H), 3.71–3.65 (m, 2H), 3.52 (dd, J = 6.0, 3.5 Hz, 2H), 3.47 (dd, J = 5.8, 3.4 Hz, 4H), 3.34 (t, J =5.8 Hz, 4H), 3.17 (q, J = 5.7 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.48 (d, J = 7.5 Hz, 2H). MS (ESI) m / z 751 (M + H)+.
[0201] Example 13. Synthesis of N-(3-(10H-phenoxazin-10-yl)propyl)-4- (trifluoromethoxy)benzenesulfonamide (JWJ-01-065).
[0202] Step 1: To a stirring solution of NaH (22 mg, 60%, 0.55 mmol) in 5 mL DMF at 0 °C, 10H-phenoxazine (50 mg, 0.27 mmol) in 1 ml DMF was added slowly under an argon atmosphere. About 1 h later, tert-butyl (3- bromopropyl)carbamate (97 mg, 0.41 mmol) in 1 mL DMF was dropwise added to the mixture under stirring at 0 °C. Then the reaction mixture was warmed to room temperature and further stirred for 12 h. The saturated NH4Cl solution was added to the reaction mixture, which was extracted with ethyl acetate (3 × 20 mL). The organic phase was combined, dried over magnesium sulfate, filtered, and concentrated to give the crude product, which was further purified via column chromatography to give intermediate (JWJ- 01-048-2, 72 mg, 77%) for the next step.1H NMR (500 MHz, DMSO-d6) δ 7.05 (t, J = 5.4 Hz, 1H), 6.80 (ddd, J = 8.1, 6.0, 3.0 Hz, 2H), 6.70–6.61 (m, 6H), 3.58–3.51 (m, 2H), 3.06 (q, J = 6.2 Hz, 2H), 1.68 (p, J =6.7 Hz, 2H), 1.40 (s, 9H). Step 2: JWJ-01-048-2 (72 mg, 0.27 mmol) was treated with a 1:1 (v / v) mixture of DCM / TFA (5 mL / mmol) for 30 min. Upon the completion of the removal of the Boc group indicated by UPLC, excess TFA and DCM were evaporated under reduced pressure. After putting on the high vacuum for another 2 hours to fully remove TFA, the crude material was subjected to the next step without further purification. Step 3: A solution of deprotected intermediate (50 mg, 0.21 mmol) in DMF (2 mL) was cooled to 0 °C, treated with DIPEA (72 uL, 0.42 mmol), and 4-trifluoromethoxybenzenesulfonyl chloride (60 mg, 39 uL, 0.23 mmol). The mixture was warmed to 25 °C, and stirred for additional 2 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was diluted with DMSO to 5 mL and filtered through a 13 mm, syringe filter (0.45 um, PTFE). The resulting filtrate was loaded on the preparative HPLC, which yielded the desired compound as a TFA salt (51 mg, 40%) with 94% purity.1H NMR (500 MHz, DMSO-d6) δ 7.97–7.86 (m, 3H), 7.61 (d, J = 8.3 Hz, 2H), 6.80 (dt, J = 6.3, 4.4 Hz, 2H), 6.64 (ddt, J = 7.8,5.8, 2.5 Hz, 6H), 3.54 (t, J = 8.0 Hz, 2H), 2.96 (t, J = 6.8 Hz, 2H), 1.63 (t, J = 7.9 Hz, 2H). MS (ESI) m / z 465 (M + H)+.
[0203] Example 14. Synthesis of N-(3-(10H-phenoxazin-10-yl)propyl)-N-methyl-4- (trifluoromethoxy)benzenesulfonamide (JWJ-01-122).
[0204] To a stirring solution of JWJ-01-065 (50 mg, 0.11 mmol) in anhydrous THF (2 mL) at -78 °C, n-BuLi solution (1.6 M, 0.1 mL) was added slowly under an argon atmosphere. About 1 h later, iodomethane solution (2 M,61 uL) was added to the mixture. Then the reaction mixture was warmed to room temperature and further stirred for 12 h. The saturated NH4Cl solution was added to the reaction mixture, which was extracted with ethyl acetate (3 × 20 mL). The organic phase was combined, dried over magnesium sulfate, filtered, and concentrated to give the crude product, which was further purified via preparative HPLC, which yielded the desired compound as a TFA salt (25 mg, 37%) with 96% purity.1H NMR (599 MHz, DMSO-d6) δ 7.96–7.90 (m, 2H), 7.59 (d, J = 8.4 Hz, 2H), 6.86–6.81 (m, 2H), 6.70–6.62 (m, 6H), 3.59 (t, J = 7.8 Hz, 2H), 3.17 (t, J = 7.1 Hz, 2H), 2.76 (s, 3H), 1.77 (q, J = 7.4 Hz, 2H). MS (ESI) m / z 479 (M + H)+.
[0205] Example 15. Synthesis of tert-Butyl (7-oxo-7-(((10-(3-((4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3- yl)methyl)amino)heptyl)carbamate (JWJ-01-098).
[0206] Step 1: To a stirring solution of NaH (42 mg, 60%, 1.1 mmol) in 5 mL DMF at 0 °C, 10H-phenoxazine-3-carbonitrile (100 mg, 0.48 mmol) in 1 ml DMF was added slowly under an argon atmosphere. About 1 h later, tert-butyl (3-bromopropyl)carbamate (126 mg, 0.53 mmol) in 1 mL DMF was dropwise added to the mixture under stirring at 0 °C. Then the reaction mixture was warmed to room temperature and further stirred for 12 h. The saturated NH4Cl solution was added to the reaction mixture, which was extracted with ethyl acetate (3 × 20 mL). The organic phase was combined, dried over magnesium sulfate, filtered, and concentrated to give the crude product, which was further purified via column chromatography to give intermediate (JWJ- 01-048-1, 20 mg, 11%) for the next step.1H NMR (500 MHz, DMSO-d6) δ 7.27 (dd, J = 8.4, 2.0 Hz, 1H), 7.04 (d, J = 5.8 Hz, 2H), 6.88– 6.83 (m, 1H), 6.80–6.72 (m, 3H), 6.68 (dd, J = 7.9, 1.5 Hz, 1H), 3.64–3.55 (m, 2H), 3.10– 3.00 (m, 2H), 1.67 (p, J = 7.0 Hz, 2H), 1.39 (s, 9H). Step 2: JWJ-01-048-1 (37 mg, 0.10 mmol) was treated with a 1:1 (v / v) mixture of DCM / TFA (5 mL / mmol) for 30 min. Upon the completion of the removal of the Boc group indicated by UPLC, excess TFA and DCM were evaporated under reduced pressure. After putting on the high vacuum for another 2 hours to fully remove TFA, the crude material was subjected to the next step without further purification. Step 3: A solution of deprotected intermediate (37 mg, 0.10 mmol) in DMF (2 mL) was cooled to 0 °C, treated with DIPEA (72 uL, 0.42 mmol), and 4- trifluoromethoxybenzenesulfonyl chloride (29 mg, 19 uL, 0.11 mmol). The mixture was warmed to 25 °C, and stirred for additional 2 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The crude material (37 mg, 99%) wassubjected to the next step without further purification.1H NMR (500 MHz, DMSO-d6) δ 7.96–7.87 (m, 3H), 7.61 (dq, J = 7.8, 1.1 Hz, 2H), 7.26 (dd, J= 8.4, 2.0 Hz, 1H), 7.01 (d, J = 1.9 Hz, 1H), 6.88–6.81 (m, 1H), 6.77–6.71 (m, 3H), 6.66 (dd, J = 7.8, 1.5 Hz, 1H), 3.61–3.54 (m, 2H), 2.96 (t, J = 6.8 Hz, 2H), 1.60 (p, J = 6.9 Hz, 2H). Step 4: To a flame-dried two-neck round bottom flask (50 mL) with nitrogen balloon, 0.3 mL lithium aluminum hydride solution (1M in THF) was charged and cooled to 0 °C. The system was purged with nitrogen gas three times. JWJ-01-077-SM (50 mg, 0.10 mmol) solution in THF (1 mL) was added dropwise. The mixture was then heated to 50 °C for 12 h. Then the cloudy solution was cooled to 0 °C before the additions of DI water and 3M NaOH solution dropwise. After the filtration, the filter cake was washed with methanol and the combined organic phase was dried with anhydrous MgSO4, which under reduced pressure yielded the crude product (50 mg, 99%) without further purification.1H NMR (500 MHz, DMSO-d6) δ 7.95 (s, 2H), 7.89 (td, J = 6.2, 5.7, 2.5 Hz, 3H), 7.61–7.56 (m, 2H), 6.85 (dd, J = 8.3, 2.1 Hz, 1H), 6.82–6.77 (m, 1H), 6.73 (d, J = 2.0 Hz, 1H), 6.69–6.61 (m, 4H), 3.81 (s, 2H), 3.52 (d, J = 8.0 Hz, 2H), 2.91 (q, J = 6.4 Hz, 2H), 1.64–1.55 (m, 2H). Step 5: JWJ-01-077 (400 mg, 0.81 mmol), 7- ((tert-butoxycarbonyl)amino)heptanoic acid (199 mg, 0.81 mmol), HATU (462 mg, 1.22 mmol), and DIPEA (0.42 mL, 2.43 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12 h. The mixture was partitioned between DI water (20mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-098, 340 mg, 58%).1H NMR (500 MHz, DMSO-d6) δ 8.17 (t, J = 5.9 Hz, 2H), 7.96–7.90 (m, 3H), 7.62–7.58 (m, 2H), 6.82–6.73 (m, 2H), 6.66–6.58 (m, 4H), 6.52 (d, J = 2.0 Hz, 1H), 4.05 (d, J = 5.9 Hz, 2H), 3.61 (tt, J = 6.6, 3.3 Hz, 2H), 3.56 – 3.50 (m, 2H), 3.14 (dt, J = 7.4, 3.7 Hz, 2H), 2.94 (q, J = 6.5 Hz, 2H), 2.86 (d, J = 6.7 Hz, 2H), 2.09 (t, J = 7.4 Hz, 2H), 1.62 (p, J = 6.7 Hz, 2H), 1.49 (d, J = 7.4 Hz, 2H), 1.36 (d, J = 1.8 Hz, 11H).
[0207] Example 16. Synthesis of tert-Butyl (7-(((10-(3-((N-methyl-4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)amino)-7- oxoheptyl)carbamate (JWJ-01-117).
[0208] To a stirring solution of NaH (10 mg, 60%, 0.24 mmol) in 3 mL THF at 0 °C, JWJ- 01-098 (85 mg, 0.12 mmol) in 1 ml DMF was added slowly under an argon atmosphere. About 1 h later, iodomethane solution (2M in in tert-butyl methyl ether, 0.13 mL, 0.26 mmol) was dropwise added to the mixture under stirring at 0 °C. Then the reaction mixture was warmed to room temperature and further stirred for 12 h. The saturated NH4Cl solution was added to the reaction mixture, which was extracted with ethyl acetate (3 × 20 mL). The organic phase was combined, dried over magnesium sulfate, filtered, and concentrated to give the crude product, which was further purified via column chromatography to give intermediate (JWJ-01-117, 80 mg, 92%) for the next step.1H NMR (500 MHz, DMSO-d6) δ 8.21 (dt, J = 24.4, 5.9 Hz, 1H), 7.96–7.92 (m, 2H), 7.92–7.82 (m, 1H), 7.78 (qd, J = 8.2, 7.2, 2.9 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 6.83 (ddd, J = 8.5, 5.6, 3.4 Hz, 1H), 6.79–6.71 (m, 1H), 6.70–6.60 (m, 4H), 6.54 (dd, J = 7.1, 1.9 Hz, 1H), 4.06 (dd, J = 6.6, 4.3 Hz, 2H), 3.57 (t, J = 7.8 Hz, 2H), 3.14 (t, J = 7.1 Hz, 2H), 2.88 (q, J = 6.5 Hz, 2H), 2.69 (s, 3H), 2.10 (t, J = 7.4 Hz, 2H), 1.71 (p, J = 7.3 Hz, 2H), 1.55–1.43 (m, 2H), 1.36 (s, 9H), 1.28–1.20 (m, 4H).
[0209] Example 17. Synthesis of 7-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-((10- (3-((4-(trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3- yl)methyl)heptanamide (JWJ-01-099).
[0210] The title compound was generated via the general procedure of HATU coupling using JWJ-01-098 (40 mg, 0.055 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (13 mg, 0.055 mmol), which yielded a while solid (6.8 mg, 12 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.68 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.20–8.14 (m, 1H), 7.96 (d, J = 6.7 Hz, 1H), 7.94–7.89 (m, 3H), 7.80 (t, J = 5.6 Hz, 1H), 7.61 (d, J = 3.8 Hz, 1H), 7.59 (d, J = 5.4 Hz, 2H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 6.86– 6.49 (m, 7H), 4.05 (s, 2H), 3.52 (s, 2H), 3.04 (t, J = 7.8 Hz, 2H), 2.99 (t, J = 6.4 Hz, 2H), 2.89 (s, 2H), 2.46 (t, J = 7.6 Hz, 2H), 2.04 (t, J = 7.4 Hz, 2H), 1.62 (s, 2H), 1.39 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 6.9 Hz, 2H), 1.14 (p, J = 3.4 Hz, 4H). MS (ESI) m / z 843 (M + H)+.
[0211] Example 18. Synthesis of 7-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-((10- (3-((N-methyl-4-(trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3- yl)methyl)heptanamide (JWJ-01-118).
[0212] The title compound was generated via the general procedure of HATU coupling using JWJ-01-117 (80 mg, 0.11 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (26 mg, 0.11 mmol), which yielded a while solid (2.3 mg, 2.2 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.68 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.18 (s, 1H), 7.96 (d, J = 6.7 Hz, 1H), 7.94–7.89 (m, 2H), 7.80 (t, J = 5.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.58 (s, 1H), 7.34 (dd, J = 8.3, 1.4 Hz, 1H), 6.82 (s, 1H), 6.64 (s, 5H), 6.53 (s, 1H), 4.06 (s, 2H), 3.56 (s, 2H), 3.13 (s, 2H), 3.03 (t, J = 7.8 Hz, 2H), 3.01–2.97 (m, 2H), 2.73 (s, 3H), 2.46 (t, J = 7.6 Hz, 2H), 2.04 (t, J = 7.4 Hz, 2H), 1.70 (s, 2H), 1.40 (t, J = 7.2 Hz, 2H), 1.30 (q, J = 6.9 Hz, 2H), 1.14 (dt, J = 7.1, 3.5 Hz, 4H). MS (ESI) m / z 857 (M + H)+.
[0213] Example 19. Synthesis of 3-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethoxy)-N-((10-(3-((4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)propenamide (JWJ-01-116).
[0214] The title compound was generated via the general procedure of HATU coupling using JWJ-01-111 (75 mg, 0.094 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (23 mg, 0.094 mmol), which yielded a while solid (5.0 mg, 2 %) with 98% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.8Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.25 (t, J = 5.8 Hz, 1H), 7.99–7.88 (m, 5H), 7.60 (ddd, J = 11.8, 4.3, 2.2 Hz, 3H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 6.79 (s, 1H), 6.61 (s, 5H), 6.52 (s, 1H), 4.06 (s, 2H), 3.65–3.57 (m, 2H), 3.47 (d, J = 16.5 Hz, 5H), 3.42 (q, J = 2.0 Hz, 3H), 3.34 (t, J = 5.9 Hz, 2H), 3.17 (q, J = 5.7 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.93 (s, 3H), 2.86 (s, 1H), 2.48 (d, J = 7.5 Hz, 2H), 2.35 (q, J = 6.2 Hz, 2H), 1.62 (s, 2H). MS (ESI) m / z 919 (M + H)+.
[0215] Example 20. Synthesis of 3-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethoxy)-N-((10-(3-((N-methyl-4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)propenamide (JWJ-01-120).
[0216] The title compound was generated via the general procedure of HATU coupling using JWJ-01-119 (47 mg, 0.059 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (14 mg, 0.059 mmol), which yielded a while solid (10.1 mg, 15 %) with 94% purity.1H NMR (500 MHz, DMSO-d6) δ 13.02 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.31 (d, J = 8.2 Hz, 1H), 8.26 (t, J = 5.8 Hz, 1H), 7.99–7.89 (m, 4H), 7.65–7.56 (m, 3H), 7.34 (dd, J = 8.1, 1.4 Hz, 1H), 6.82 (s, 1H), 6.64 (s, 6H), 3.61 (t, J = 6.3 Hz, 2H), 3.56 (s, 3H), 3.49 (d, J = 2.3 Hz, 1H), 3.47–3.38 (m, 7H), 3.34 (t, J = 5.9 Hz, 2H), 3.19 (d, J = 5.7 Hz, 1H), 3.19–3.11 (m, 3H), 3.03 (t, J = 7.6 Hz, 2H), 2.90 (s, 1H), 2.87 (s, 1H), 2.73 (s, 3H), 2.48 (d, J = 7.6 Hz, 1H), 2.35 (t, J = 6.3 Hz, 2H), 1.70 (s, 2H). MS (ESI) m / z 933 (M + H)+.
[0217] Example 21. Synthesis of 7-(2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetamido)-N-((10-(3-((4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H- phenoxazin-3-yl)methyl)heptanamide (JWJ-01-102).
[0218] The title compound was generated via the general procedure of HATU coupling using JWJ-01-098 (40 mg, 0.055 mmol) and 2-((5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2- yl)oxy)acetic acid (18 mg, 0.055 mmol), which yielded a while solid (2.8 mg, 4.7 %) with 97% purity.1H NMR (500 MHz, DMSO-d6) δ 13.17 (s, 1H), 9.76 (s, 1H), 8.67 (d, J = 6.7 Hz, 1H), 8.59 (d, J = 2.5 Hz, 1H), 8.51 (d, J = 8.2 Hz, 1H), 8.24–8.16 (m, 2H), 8.06–7.99 (m, 2H), 7.92 (dd, J = 8.5, 5.9 Hz, 3H), 7.80 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 8.3 Hz, 2H), 7.07 (d, J = 8.6 Hz, 1H), 6.79 (s, 1H), 6.62 (s, 6H), 6.49 (s, 1H), 4.77 (s, 2H), 3.52 (s, 2H), 3.09 (q, J = 6.5 Hz, 2H), 2.94 (s, 3H), 2.88 (s, 1H), 2.09 (t, J = 7.4 Hz, 2H), 1.61 (s, 2H), 1.49 (t, J = 7.1 Hz, 2H), 1.41 (t, J = 6.9 Hz, 2H), 1.23 (d, J = 7.0 Hz, 4H). MS (ESI) m / z 922 (M + H)+.
[0219] Example 22. Synthesis of 9-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-((10- (3-((4-(trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3- yl)methyl)nonanamide (JWJ-01-114).
[0220] The title compound was generated via the general procedure of HATU coupling using JWJ-01-098 (74 mg, 0.099 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (24 mg, 0.099 mmol), which yielded a while solid (6.8 mg, 7.0 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.68 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.17 (s, 1H), 7.96 (d, J = 6.7 Hz, 1H), 7.95–7.88 (m, 3H), 7.78 (t, J = 5.7 Hz, 1H), 7.62–7.56 (m, 3H), 7.34 (dd, J = 8.1, 1.4 Hz, 1H), 6.84–6.37 (m, 7H), 4.05 (s, 2H), 3.03 (t, J = 7.5 Hz, 2H), 2.97 (dt, J = 18.8, 9.4 Hz, 4H), 2.46 (t, J = 7.5 Hz, 2H), 2.06 (t, J = 7.4 Hz, 2H), 1.62 (s, 2H), 1.41 (q, J = 7.3 Hz, 2H), 1.28 (p, J = 7.0 Hz, 2H), 1.11 (s, 8H). MS (ESI) m / z 871 (M + H)+.
[0221] Example 23. Synthesis of 3-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)-N-((10-(3-((4- (trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)propenamide (JWJ-01-115).
[0222] The title compound was generated via the general procedure of HATU coupling using JWJ-01-111 (118 mg, 0.157 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (37.7 mg, 0.157 mmol), which yielded a while solid (7.4 mg, 4.7 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.02 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.31 (d, J = 8.1 Hz, 1H), 8.25 (t, J = 6.1 Hz, 1H), 7.98–7.89 (m, 5H), 7.62–7.56 (m, 3H), 7.34 (dd, J = 8.1, 1.4 Hz, 1H), 6.78 (s, 1H), 6.56 (d, J = 54.8 Hz, 6H), 4.06 (s, 2H), 3.58 (t, J = 6.3 Hz, 4H), 3.53–3.48 (m, 2H), 3.43 (s, 4H), 3.35 (t, J = 5.8 Hz, 2H), 3.18 (q, J = 5.7 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.93 (s, 2H), 2.34 (t, J = 6.3 Hz, 2H), 1.61 (s, 2H). MS (ESI) m / z 875 (M + H)+.
[0223] Example 24. Synthesis of 14-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-((10- (3-((4-(trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)- 3,6,9,12- tetraoxatetradecanamide (JWJ-01-096).
[0224] The title compound was generated via the general procedure of HATU coupling using JWJ-01-082 (60 mg, 0.073 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (17 mg, 0.073 mmol), which yielded a while solid (12.2 mg, 4.7 %) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 13.02 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 8.12 (s, 1H), 7.99–7.90 (m, 4H), 7.90 (d, J = 5.8 Hz, 1H), 7.63–7.56 (m, 3H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 6.62 (s, 8H), 4.10 (s, 2H), 3.93–3.90 (m, 4H), 3.61–3.52 (m, 4H), 3.51–3.38 (m, 8H), 3.33 (t, J = 5.9 Hz, 2H), 3.17 (q, J = 5.8 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.93 (s, 2H), 2.47 (d, J = 7.6 Hz, 1H), 1.62 (s, 2H). MS (ESI) m / z 949 (M + H)+.
[0225] Example 25. Synthesis of 1-(3-(5H-pyrido[4,3-b]indol-7-yl)propanamido)-N-((10- (3-((4-(trifluoromethoxy)phenyl)sulfonamido)propyl)-10H-phenoxazin-3-yl)methyl)- 3,6,9,12-tetraoxapentadecan-15-amide (JWJ-01-101).
[0226] The title compound was generated via the general procedure of HATU coupling using JWJ-01-100 (35 mg, 0.042 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (11 mg, 0.046 mmol), which yielded a while solid (5.1 mg, 11 %) with 98% purity.1H NMR (500 MHz, DMSO-d6) δ 13.04 (s, 1H), 9.67 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.25 (t, J = 5.9 Hz, 1H), 7.99–7.89 (m, 5H), 7.63–7.56 (m, 3H), 7.34 (d, J = 8.1 Hz, 1H), 6.79 (s, 1H), 6.62 (s, 5H), 6.52 (s, 1H), 4.06 (s, 2H), 3.60 (t, J = 6.4 Hz, 2H), 3.48 (d, J = 4.6 Hz, 4H), 3.45 (q, J = 4.9, 4.4 Hz, 4H), 3.42 (s, 4H), 3.34 (t, J = 5.8 Hz, 2H), 3.18 (q, J = 5.8 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.91 (d, J = 27.3 Hz, 4H), 2.48 (d, J = 7.4 Hz, 2H), 2.35 (t, J = 6.3 Hz, 2H), 1.25 (q, J = 6.7, 6.2 Hz, 2H). MS (ESI) m / z 963 (M + H)+.
[0227] Example 26. Synthesis of N-benzyl-2-chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)acetamide (JWJ-01-028).
[0228] Step 1: 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine (100 mg, 0.66 mmol), benzyl bromide (113 mg, 0.66 mmol), and potassium carbonate (137 mg, 0.99 mmol) were charged into 20 mL scintillation vial. After adding 10 mL DMF, the mixture was heated to 70 °C andstirred for 2 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-011, 82 mg, 51%) for next step. Step 2: To a solution of JWJ-01- 011 (82 mg, 0.34 mmol) in DCM (10 mL), 2-choloracetyl chloride (46 mg, 32 uL, 0.41 mmol) and triethylamine (60 uL, 0.41 mmol) were added and the reaction stirred overnight. Upon reaction completion the crude was purified via preparative HPLC, which yielded the desired compound as a TFA salt (74 mg, 51%) with 99% purity.1H NMR (500 MHz, DMSO-d6) δ 7.33–7.27 (m, 2H), 7.27–7.21 (m, 1H), 7.21–7.17 (m, 2H), 6.85–6.78 (m, 2H), 6.67 (dd, J = 8.6, 2.6 Hz, 1H), 4.81 (s, 2H), 4.25–4.18 (m, 4H), 4.09 (s, 2H). MS (ESI) m / z 318 (M + H)+.
[0229] Example 27. Synthesis of 4-((2-Chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)acetamido)methyl)benzoic acid (JWJ-01-044).
[0230] Step 1: 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine (100 mg, 0.66 mmol), methyl 4- (bromomethyl)benzoate (152 mg, 0.66 mmol), and potassium carbonate (137 mg, 0.99 mmol) were charged into 20 mL scintillation vial. After adding 10 mL DMF, the mixture was heated to 70 °C and stirred for 2 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-040, 139 mg, 70%) for next step. Step 2: To a solution of JWJ-01-040 (82 mg, 0.46 mmol) in DCM (10 mL), 2-choloracetyl chloride (63 mg, 44 uL, 0.56 mmol) and triethylamine (78 uL, 0.56 mmol) were added and the reaction stirred overnight. Upon reaction completion, the mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-042, 119 mg, 68%)for next step. Step 3: To a solution of JWJ-01-042 (119 mg, 0.32 mmol) in MeOH (3 mL), sodium hydroxide (25 mg, 0.63 mmol) was added, followed by 3 mL DI water. The mixture was stirred overnight. Upon reaction completion monitored by UPLC, additional 6 mL DI water was charged, and the pH value was adjusted to 2 to 3 by 1 M HCl solution. The formed precipitate was collected via filtration and dried under the high vacuum to yield the desired acid (JWJ-01-044, 115 mg, 99%).1H NMR (500 MHz, DMSO-d6) δ 8.07 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 2.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.74 (dd, J = 8.6, 2.5 Hz, 1H), 4.94 (s, 2H), 4.22 (s, 4H), 4.14 (s, 2H).
[0231] Example 28. Synthesis of tert-Butyl (6-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)hexyl)carbamate (JWJ-01-121).
[0232] 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), tert-butyl (6- aminohexyl)carbamate (18 mg, 0.083 mmol), HATU (41 mg, 0.11 mmol), and DIPEA (44 uL, 0.25 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-121, 31 mg, 85%).1H NMR (500 MHz, DMSO-d6) δ 11.66 (s, 1H), 9.28 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.78 (t, J = 5.6 Hz, 1H), 7.44 (d, J = 5.7 Hz, 1H), 7.36 (d, J = 1.4 Hz, 1H), 7.12 (dd, J = 8.1, 1.5 Hz, 1H), 6.74 (t, J = 5.7 Hz, 1H), 2.99 (p, J = 8.1, 7.4 Hz, 4H), 2.83 (q, J = 6.7 Hz, 2H), 2.43 (t, J = 7.7 Hz, 2H), 1.36 (s, 9H), 1.28 (dd, J = 15.0, 7.2 Hz, 2H), 1.14 (q, J = 3.6 Hz, 4H).
[0233] Example 29. Synthesis of tert-Butyl (2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethyl)carbamate (JWJ-01- 104).
[0234] 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (20 mg, 0.083 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (23 mg, 0.092 mmol), HATU (41 mg, 0.11 mmol), and DIPEA (44 uL, 0.25 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-104, 22 mg, 56%).1H NMR (500 MHz, DMSO-d6) δ 11.60 (s, 1H), 9.26 (s, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.91 (t, J = 5.6 Hz, 1H), 7.42 (dd, J = 5.6, 1.1 Hz, 1H), 7.35 (d, J = 1.2 Hz, 1H), 7.11 (dd, J = 8.0, 1.4 Hz, 1H), 6.76 (s, 1H), 3.42 (s, 4H), 3.22–3.14 (m, 2H), 3.03 (q, J = 6.0 Hz, 2H), 2.97 (t, J = 7.7 Hz, 2H), 2.45 (t, J = 7.7 Hz, 2H), 1.36 (s, 9H).
[0235] Example 30. Synthesis of N-(6-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)hexyl)-4-((2-chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)acetamido)methyl)benzamide (JWJ-01-125)
[0236] The title compound was generated via the general procedure of HATU coupling using JWJ-01-121 (30 mg, 0.068 mmol) and JWJ-01-044 (25 mg, 0.068 mmol), which yielded a while solid (3.0 mg, 5 %) with 98% purity.1H NMR (500 MHz, DMSO-d6) δ 13.04 (d, J = 2.8 Hz, 1H), 9.69 (d, J = 2.8 Hz, 1H), 8.61 (dd, J = 6.6, 2.7 Hz, 1H), 8.39 (q, J = 4.9 Hz, 1H), 8.32 (dd, J = 8.1, 2.9 Hz, 1H), 7.96 (dd, J = 6.5, 2.8 Hz, 1H), 7.81 (q, J = 4.9 Hz,1H), 7.74 (dd, J = 8.3, 2.8 Hz, 2H), 7.59 (d, J = 2.6 Hz, 1H), 7.35 (dd, J = 8.1, 2.7 Hz, 1H), 7.27 (dd, J = 8.3, 2.7 Hz, 2H), 6.85–6.78 (m, 2H), 6.68 (dd, J = 8.6, 2.9 Hz, 1H), 4.87–4.83 (m, 2H), 4.21 (s, 4H), 4.11 (d, J = 2.8 Hz, 2H), 3.15 (q, J = 7.2, 6.7 Hz, 2H), 3.03 (ddd, J = 19.8, 9.9, 4.5 Hz, 4H), 2.50–2.43 (m, 2H), 1.39 (q, J = 7.2 Hz, 2H), 1.30 (q, J = 7.3 Hz, 2H), 1.18 (dp, J = 14.7, 8.7, 6.9 Hz, 4H). MS (ESI) m / z 682 (M + H)+.
[0237] Example 31. Synthesis of N-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethyl)-4-((2-chloro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)acetamido)methyl)benzamide (JWJ-01-105).
[0238] The title compound was generated via the general procedure of HATU coupling using JWJ-01-104 (30 mg, 0.068 mmol) and JWJ-01-044 (19 mg, 0.051 mmol), which yielded a while solid (2.2 mg, 5.5 %) with 97% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.68 (s, 1H), 8.62 (d, J = 6.8 Hz, 1H), 8.49 (t, J = 5.7 Hz, 1H), 8.32 (d, J = 8.2 Hz, 1H), 7.97 (d, J = 6.7 Hz, 1H), 7.93 (t, J = 5.7 Hz, 1H), 7.77–7.72 (m, 2H), 7.59 (s, 1H), 7.34 (dd, J = 8.2, 1.4 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 6.85–6.80 (m, 2H), 6.68 (dd, J = 8.5, 2.5 Hz, 1H), 4.85 (s, 2H), 4.20 (s, 4H), 4.11 (s, 2H), 3.50–3.42 (m, 6H), 3.36 (dt, J = 14.4, 5.7 Hz, 4H), 3.17 (q, J = 5.8 Hz, 2H), 3.03 (t, J = 7.7 Hz, 2H), 2.48 (d, J = 7.6 Hz, 2H). MS (ESI) m / z 714 (M + H)+.
[0239] Example 32. Synthesis of tert-Butyl (6-(4-((N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)propionamido)methyl)benzamido)hexyl)carbamate (JWJ-01-257-Boc).
[0240] Step 1: JWJ-01-040 (175 mg, 58 mmol), propionic acid (53 uL, 70 mmol), HATU (333 mg, 0.88 mmol), and DIPEA (306 uL, 1.75 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-258-HATU- 1, 103 mg, 50%).1H NMR (500 MHz, DMSO-d6) δ 7.86 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 6.81 (d, J = 8.5 Hz, 1H), 6.75 (d, J = 2.5 Hz, 1H), 6.64–6.60 (m, 1H), 4.85 (s, 2H), 4.21 (s, 4H), 2.09 (q, J = 7.6 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). Step 2: To a solution of JWJ- 01-258-HATU-1 (103 mg, 0.29 mmol) in MeOH (3 mL), sodium hydroxide (25 mg, 0.58 mmol) was added, followed by 3 mL DI water. The mixture was stirred overnight. Upon reaction completion monitored by UPLC, additional 6 mL DI water was charged, and the pH value was adjusted to 2 to 3 by 1 M HCl solution. The formed precipitate was collected via filtration and dried under the high vacuum to yield the desired acid (JWJ-01-258-Hydrolysis, 98 mg, 99%). Step 3: JWJ-01-258-Hydrolysis (33 mg, 0.096 mmol), 1-((tert- butoxycarbonyl)amino)-6-aminohexane (23 mg, 0.11 mmol), HATU (55 mg, 0.15 mmol), and DIPEA (0.51 uL, 0.29 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-257-Boc, 52 mg, 99%).
[0241] Example 33. Synthesis of tert-Butyl (2-(2-(2-(4-((N-(2,3- dihydrobenzo[b][1,4]dioxin-6- yl)propionamido)methyl)benzamido)ethoxy)ethoxy)ethyl)carbamate (JWJ-01-258-Boc).
[0242] JWJ-01-258-Hydrolysis (63 mg, 0.19 mmol), N-tert-butyloxycarbonyl-1,8-diamino- 3,6-dioxaoctane (55 mg, 0.22 mmol), HATU (106 mg, 0.28 mmol), and DIPEA (0.97 uL, 0.56 mmol) were charged to 20 mL scintillation vial. After adding 5 mL DMF, the mixture was stirred for 12 h. The mixture was partitioned between DI water (20 mL), and DCM (50 mL). The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was then purified via flash column chromatography, which yielded the desired compound (JWJ-01-258-Boc, 99 mg, 93%).
[0243] Example 34. Synthesis of N-(6-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)hexyl)-4-((N-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)propionamido)methyl)benzamide (JWJ-01-257).
[0244] The title compound was generated via the general procedure of HATU coupling using JWJ-01-257-Boc (52 mg, 0.096 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (18 mg, 0.076 mmol), which yielded a while solid (1.8 mg, 2.4 %) with 96% purity.1H NMR (500 MHz, DMSO-d6) δ 13.08 (s, 1H), 9.69 (s, 1H), 8.61 (d, J = 6.3 Hz, 1H), 8.38 (t, J = 5.5 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 6.6 Hz, 1H), 7.82 (t, J = 5.5 Hz, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 7.9 Hz, 2H), 6.80 (d, J = 8.5 Hz, 1H), 6.72 (s, 1H), 6.60 (d, J = 8.6 Hz, 1H), 4.82 (s, 2H), 4.20 (s, 4H), 3.15 (q, J = 6.4 Hz, 2H), 3.02 (dt, J = 17.9, 6.8 Hz, 4H), 2.47 (d, J = 7.7 Hz, 2H), 2.08 (q, J = 7.1 Hz, 2H), 1.43–1.37 (m, 2H), 1.35–1.28 (m, 2H), 1.18 (t, J = 12.8 Hz, 4H), 0.95 (t, J = 7.4 Hz, 3H). MS (ESI) m / z 662 (M + H)+.
[0245] Example 35. Synthesis of N-(2-(2-(2-(3-(5H-pyrido[4,3-b]indol-7- yl)propanamido)ethoxy)ethoxy)ethyl)-4-((N-(2,3- dihydrobenzo[b][1,4]dioxin-6- yl)propionamido)methyl)benzamide (JWJ-01-258).
[0246] The title compound was generated via the general procedure of HATU coupling using JWJ-01-258-DeBoc (65 mg, 0.14 mmol) and 3-(5H-pyrido[4,3-b]indol-7-yl)propanoic acid (18 mg, 0.11 mmol), which yielded a while solid (4.4 mg, 3.9 %) with 98% purity.1H NMR (500 MHz, DMSO-d6) δ 13.03 (s, 1H), 9.68 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.46 (t, J = 5.5 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.97 (d, J = 6.7 Hz, 1H), 7.93 (t, J = 5.5 Hz, 1H), 7.74 (d, J = 7.9 Hz, 2H), 7.59 (s, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 7.8 Hz, 2H), 6.79 (d, J = 8.6 Hz, 1H), 6.74–6.70 (m, 1H), 6.61–6.56 (m, 1H), 4.81 (s, 2H), 4.20 (s, 4H), 3.54– 3.43 (m, 6H), 3.38–3.32 (m, 4H), 3.17 (d, J = 16.9 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H), 2.47 (s, 2H), 2.08 (q, J = 7.3 Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H). MS (ESI) m / z 694 (M + H)+.
[0247] Example 36. Compounds of the Present Disclosure Selectively Dephosphorylate Tau in a Human Disease Model via PP2A activity.
[0248] The small molecules of Examples 1-35 were then assessed for their Tau dephosphorylation capacity in a neuronal model for human tauopathy disease. Induced pluripotent stem cell (iPSC)-derived neural progenitor cells (NPCs) were derived from a patient carrier of the Tau-P301L autosomal dominant mutation, and post-mitotic neurons enriched for cortical neuron subtype were then generated, as previously described (Cheng et al., 2017; Silva et al., 2016; Seo et al., 2017).
[0249] Human Neural Progenitor Cells (NPCs) were cultured as follows. Approval for work with human subjects and derived induced pluripotent stem cells (iPSCs) was obtained under the Massachusetts General Hospital / MGB-approved IRB Protocol #2010P001611 / MGH. The cell line employed in this study was derived from a femaleindividual in her 50s carrying the autosomal dominant mutation P301L (c.C1907T NCBI NM_001123066, rs63751273), diagnosed with FTD and categorized as cell line MGH2046- RC1 (DOI:10.1038 / s41467-020-16984-1, DOI:10.7554 / eLife.45457). Briefly, fibroblasts were reprogrammed into iPSCs by non-integrating methods, which were converted into cortical-like neural progenitor cells (NPCs), enriched for CNS precursors by CD133+ / CD184+ / CD271–FACS purification (DOI:10.1016 / j.stemcr.2016.08.001, DOI:10.1002 / cphg.33). NPCs were cultured at an approximate density of 75,000 cells / cm2in 6-well (Fisher Scientific Corning) or black 96-well clear bottom (Fisher Scientific Corning) plates coated with poly-ornithine (20 μg / mL in water, Sigma) and laminin (5μg / mL in PBS, Sigma), referred to as POL-coated plates, in DMEM / F12-B27 cell media [70% DMEM (Gibco), 30% Ham’s-F12 (Fisher Scientific Corning), 2% B27 (Gibco), 1% penicillin- streptomycin (Gibco)]. Media was supplemented with EGF (20 ng / mL, Sigma), FGF (20 ng / mL, Stemgent) and heparin (5 μg / mL, Sigma) to promote NPC proliferation. NPCs were routinely passaged every 2.5 days with TrypLE (Thermo Fisher) enzymatic reagent.
[0250] NPC differentiation was achieved as follows. NPCs were passaged and plated with the routine protocols, with the difference that growth factors were omitted from the cell media. Cells were cultured for a period of several weeks (6 or 8 weeks) with change of half- volume culture media twice per week (DOI: 10.1038 / s41467-020-16984-1; DOI: 10.7554 / eLife.45457; DOI: 10.1016 / j.stemcr.2016.08.001).
[0251] The compounds of the present disclosure were tested for efficacy in a model for Tau aggregation disease as follows. Tau-P301L patient derived NPCs were plated at an average density of 75,000 cells / cm2in multi-well POL plates with DMEM / F12-B27 media for differentiation. At 6-8 weeks of differentiation, neurons were treated with phosphoeditor compounds alone (doses between 0.1 nM and 10 μM) or in addition to phosphatase inhibitors or T807 (flortaucipir) compound for 6 hrs or 24 hrs. After incubation, neurons were washed with PBS, resuspended in ice-cold PBS (Corning) and pelleted at 3000 xg. Cellular pellets were flash-frozen in dry ice and kept at -80°C until needed for analysis. The commercially available compounds used were: Okadaic Acid (CAS No. 78111-17-8, Millipore Sigma 495604); LB100 (CAS No. 1026680-07-8, Selleckchem S7537); and fostriecin (CAS 87860- 39-7, Tocris 1840).
[0252] Western blots were performed as follows. Cell pellets were resuspended and lysed in 5x the pellet volume with SDS-DTT sample loading buffer (NEB), incubated for 15 min atroom temperature and boiled for 15 min. Tau protein analysis by western blot followed previously developed assays (DOI: 10.1038 / s41467-020-16984-1; DOI: 10.7554 / eLife.45457; DOI: 10.1016 / j.stemcr.2016.08.001). Prior to analysis, the lysates were spun down and loaded onto SDS-PAGE gels. Electrophoresis was performed with the Novex NuPAGE SDS-PAGE Gel System (Invitrogen). Proteins were transferred from the gel onto PVDF membranes (EMD Millipore) using standard procedures (Bio-Rad wet transfer system). Membranes were blocked in 5% (w / v) BSA (Sigma) in Tris-buffered saline with Tween-20 (TBST, Boston Bio-Products), incubated overnight with primary antibody (below) at 4°C, followed by corresponding HRP-linked secondary antibody at 1:4000 dilution (Cell Signaling Technology). Blots were developed with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher) according to manufacturer’s instructions, exposed to autoradiographic films (LabScientific by ThermoFischer), and scanned on an Epson Perfection V800 Photo Scanner. Protein bands’ densitometry (pixel mean intensity in arbitrary units, a.u.) was measured with ImageJ, normalized to the respective internal control β-Actin band, and shown relative to the Vehicle (DMSO, 0 μM compound) control. Calculations were done in Microsoft Excel and graphs were prepared in GraphPad Prism 10.
[0253] Antibodies used in the western blots are as follows: total Tau TAU5 (Invitrogen AHB0042), P-Tau S396 (Invitrogen / Thermo 44752G), P-Tau S202 / T205 (AT8, Thermo Scientific MN1020), P-Tau S262 (AbCam ab92627), PP2Ac (Fisher Scientific BD610556), P-PP2A Y307 (Invitrogen PA5-36874), β-Actin (Sigma A1978).
[0254] FIG. 1A shows the proposed mechanism of action of the compounds of the present disclosure, while FIGs. 1B and 1C show how T807 and PP2A inhibitors were used to confirm that the compounds of the present technology require binding to Tau and selectively dephosphorylate Tau via PP2A activity, respectively.
[0255] FIGs. 2A-6E are western blots, and densitometric quantifications thereof, showing the abundance of total Tau (TAU5), pTau AT8 (S202 / T205), pTau S262, and ratios thereof, in Tau-P301L patient derived 6-week differentiated neurons, treated with varying concentrations of the indicated small molecule for 24h. JWJ-1-002, JWJ-1-008, JWJ-1-099, JWJ-1-116, JWJ-1-102, JWJ-1-115, JWJ-1-096, JWJ-1-123, JWJ-1-027, JWJ-1-085, JWJ-1- 010, JWJ-1-028, JWJ-1-125, and JWJ-1-122 were identified as selectively reducing the prevalence of phosphorylated Tau with or without effect on total tau. JWJ-1-115, JWJ-1-096, JWJ-1-123, JWJ-1-085, and JWJ-1-125 were selected for further analysis.
[0256] FIGs. 7A-7F show the results of western blots of Tau-P301L patient derived differentiated neurons (at 6 weeks) treated with varying concentrations of JWJ-01-115, JWJ- 01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 for 24 hours. Western blots assayed total levels of Tau (TAU5), pTau S396, pTau AT8 (S202 / T205), pTau S262, PP2A subunit c (PP2Ac, total PP2A readout), and pPP2A Y307. Phosphorylation at the Y307 residue inactivates PP2A. As seen in the graphs of the densitometric quantification of the western blots, each of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257, at one or more concentrations, caused a selective decrease in one or more forms of phosphorylated Tau, while increasing the relative amount of activated PP2A, as indicated by a decreased in the pPP2A-Y307 / total PP2A ratio.
[0257] FIGs. 8A-8F show the results of western blots of Tau-P301L patient derived differentiated neurons (at 6 weeks) treated with varying concentrations of JWJ-01-115, JWJ- 01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 for 6 hours. Western blots assayed total levels of Tau (TAU5), pTau S396, pTau AT8 (S202 / T205), pTau S262, PP2A subunit c (PP2Ac, total PP2A readout), and pPP2A Y307. Phosphorylation at the Y307 residue inactivates PP2A. As seen in the graphs of the densitometric quantification of the western blots, each of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257, at one or more concentrations, caused a selective decrease in one or more forms of phosphorylated Tau, while increasing the relative amount of activated PP2A, as indicated by a decreased in the pPP2A-Y307 / total PP2A ratio.
[0258] FIG. 9 shows the effect of treatment with several control compounds, JWJ-1-065, FMF-06-124, and JWJ-1-028, on the abundance of total Tau (TAU5), pTau AT8 (S202 / T205), pTau S262 and ratios thereof in Tau-P301L patient derived neurons (6-week differentiated) treated with varying concentrations of the compounds for 24 hours. Relative levels were determined via densitometric quantification of western blots for the respective proteins in treated neurons, normalized to Actin and shown relative to vehicle control (0μM). In contrast to the Tau dephosphorylation activity demonstrated in FIGs. 2A-3E for JWJ-01- 115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257, the control compounds were not able to decrease the relative abundance of phosphorylated Tau isoforms relative to total Tau levels.
[0259] FIG. 10 shows the abundance of (top) total Tau (TAU5), pTau AT8 (S202 / T205), pTau S262, and (bottom) pPP2A Y307, PP2A, and ratios thereof, in Tau-P301L patientderived 6-week differentiated neurons, treated with DMSO (vehicle control), T807 (a binder of misfolded Tau), the PP2A inhibitor okadaic acid (O.A.), the PP2A inhibitor LB100, or the PP2A inhibitor Fostriecin. Relative levels were determined via densitometric quantification of western blots for the respective proteins in treated neurons, normalized to internal control Actin and shown as relative level changes to DMSO. As expected, the PP2A inhibitors led to an increased ratio in pPP2A / total PP2A, as well as a trend for Tau accumulation.
[0260] FIGs. 11A-11B show that co-treatment of Tau-P301L patient derived neurons with JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 and excess / high concentration T807 partially or completely rescued the effect of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257, on total Tau and pTau, demonstrating that binding to Tau (i.e., ternary complex formation) is required for efficacy of the small molecules. This demonstrates that the compounds of the present technology require Tau binding to promote Tau dephosphorylation and subsequent reduction in pTau and total Tau levels.
[0261] FIGs. 12A-12B show that co-treatment of Tau-P301L patient derived neurons with JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 and okadaic acid, a non-competitive, reversible inhibitor of PP1 and PP2A, resulted in partial or complete inhibition of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, and JWJ-01-257. FIGs.13A-13B show that co-treatment of Tau-P301L patient derived neurons with JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 and LB100, a PP2A inhibitor, resulted in partial or complete inhibition of JWJ-01-115, JWJ-01- 096, JWJ-01-123, JWJ-01-085, JWJ-01-125, and JWJ-01-257. FIGs. 14A-14B show that co- treatment of Tau-P301L patient derived neurons with JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, or JWJ-01-257 and fostriecin, a PP2A inhibitor, resulted in partial or complete inhibition of JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, and JWJ-01-257. Taken together, these results demonstrate that JWJ-01-115, JWJ-01-096, JWJ-01-123, JWJ-01-085, JWJ-01-125, and JWJ-01-257 are capable of selectively dephosphorylating Tau via a PP2A mediated mechanism.
[0262] Accordingly, this example shows that the compounds of the present technology are effective for dephosphorylating Tau in a neuronal model for human tauopathies, and therefore the compounds of the present technology are useful for treating Tau aggregation and tauopathies generally.EQUIVALENTS
[0263] While certain embodiments have been illustrated and described, it should be understood that changes and modifications can be made therein in accordance with ordinary skill in the art without departing from the technology in its broader aspects as defined in the following claims.
[0264] The embodiments, illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including,” “containing,” etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the claimed technology. Additionally, the phrase “consisting essentially of” will be understood to include those elements specifically recited and those additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The phrase “consisting of” excludes any element not specified.
[0265] The present disclosure is not to be limited in terms of the particular embodiments described in this application. Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and compositions within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, compositions, or biological systems, which can of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0266] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0267] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member.
[0268] All publications, patent applications, issued patents, and other documents referred to in this specification are herein incorporated by reference as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions that are contained in text incorporated by reference are excluded to the extent that they contradict definitions in this disclosure.
[0269] Other embodiments are set forth in the following claims.
Claims
CLAIMS What is claimed is:
1. A compound of Formula I, II, III, or IV: ,R1is H or alkyl; R2is H or alkyl; R3-R8are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R4and R5or R7and R8may join together to form a fused ring;L1is a linking group that is alkylene or a group of Formula AFormula A indicates the end that binds to Ar1; R34-R37are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R34and R35or R36and R37may join together to form a fused ring; L2is a linking group that is a group of Formula B, C, D, or E:where Ar2in Formula B, C, and D indicates the end that binds to Ar2; R30, R31, R38, R39, and R40are individually alkylenyl groups, polyethylene glycol groups, or polypropylene glycol groups; R32, R33, and R50are individually H or alkyl; R41-R44are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or R41and R42or R43and R44may join together to form a fused ring;Ar2is a group of FormulaAr3is a group of FormulaR9is -CH2-, -CH2CH2-, -S-, or -O-; R10-R17are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R9-R16may join together to form a fused ring; L3is an alkylenyl group; R51-R57are each individually H, alkyl, F, Cl, Br, I, NO2, or CN, or any two adjacent R51-R57may join together to form a fused ring; and R58is H, a group of formula -CH2NR59C(O)R60NR61Pr, or a group of formula -CH2NR59C(O)R60NR61Pr; R59and R61are individually H or alkyl; R60is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; Pr is H, alkyl, an amine protecting group, a group of formula -C(O)R62Ar1, or a group of Formula E; R62is an alkylenyl group, polyethylene glycol group, or polypropylene glycol group; R70is H, -C(O)OH, or -C(O)N(R59)R60NR61Pr; and R71is H, F, Cl, Br, or I.
2. The compound of claim 1, wherein the compound is of Formula I and each of R1and R32is individually H, methyl, or ethyl; each of R2-R8, R10-R15, R17, and R34-R37is H; and R16is F, Cl, or Br.
3. The compound of any one of claims 1-2, wherein the compound is of Formula I and L1is methylene, ethylene, propylene, or butylene.
4. The compound of any one of claims 1-3, wherein the compound is of Formula I and L1is a group of Formula A.
5. The compound of any one of claims 1-4, wherein the compound is of Formula I and R31is methylene, ethylene, propylene, or butylene; and R30is C4-C10alkylene, - (CH2CH2O)n-CH2CH2-, wherein n is 1 to 10.
6. The compound of any one of claims 1-5, wherein the compound is of Formula I and R9is - CH2CH2-.
7. The compound of any one of claims 1-6, wherein the compound is of Formula I, L2is of Formula C, and R38is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10.
8. The compound of any one of claims 1-7, wherein the compound is of Formula I, L2is of Formula B, and R30is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and R39is methylene, ethylene, propylene, or butylene, wherein n is 1 to 10.
9. The compound of any one of claims 1-8, wherein the compound is of Formula I, L2is of Formula D, and R40is C4-C10alkylene or -(CH2CH2O)n-CH2CH2-, and each of R41- R44is H.
10. The compound of claim 1, wherein the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or -(CH2CH2O)n- CH2CH2-; and Pr is H, methyl, a tert-butyloxycarbonyl (boc) group, or a group of formula -C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H.
11. The compound of any one of claims 1-4, wherein the compound is of Formula I, L2is of Formula B, R31is methylene, ethylene, propylene, or butylene; and R30is - (CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, R9is -CH2CH2-, and R16is Cl.
12. The compound of any one of claims 1-4, wherein the compound is of Formula I, L2is of Formula C, R38is -C4-C10alkylenyl-, -(CH2CH2O)n-CH2CH2-, wherein n is 1 to 10, and R39is methylene, ethylene, propylene, or butylene.
13. The compound of any one of claims 1-4, wherein the compound is of Formula I, L1is methylene, ethylene, propylene, or butylene; R40is -C4-C10alkylenyl-, -(CH2CH2O)n- CH2CH2-, wherein n is 1 to 10.
14. The compound of claim 1, wherein the compound is of Formula II; L3is methylene, ethylene, propylene, or butylene; R50is H, methyl, or ethyl; each of R51-R57is H; R59and R61are individually H, methyl, or ethyl; R60is C4-C10alkylene or -(CH2CH2O)n- CH2CH2- and n is 1 to 10; and Pr is a group of formula -C(O)R62Ar1, where R62is methylene, ethylene, propylene, or butylene, and R3-R8are each individually H.
15. The compound of claim 1, wherein the compound is of Formula III; R71is Cl, R70is - C(O)N(R59)R60NR61Pr, R59is H or methyl, R60is C4-C10alkylene or -(CH2CH2O)n- CH2CH2and n is 1 to 10, R61is H or methyl, and Pr is the group of formula - C(O)R62Ar1.
16. The compound of claim 1 that is any one or more of:.
17. A composition comprising the compound of any one of claims 1-16 or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof and a pharmaceutically acceptable carrier.
18. A composition comprising the compound of any one of claims 11-16, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof and a pharmaceutically acceptable carrier.
19. The composition of claims 17 or 18 wherein the composition further comprises at least one additional therapeutic agent.
20. A method for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the compound of any one of claims 1-16, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof, or the composition of any one of claims 17- 19.
21. The method of claim 20, comprising administering to the subject a therapeutically effective amount of the compound of claim 17, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof.
22. The method of claims 20 or 21, wherein administration of the compound or composition reduces Tau species levels and / or reduces the toxicity associated with cellular Tau accumulation.
23. The method of claims 20 or 21, wherein administration of the compound or composition reduces cellular oxidative stress caused by cellular accumulation of Tau protein.
24. The method of any one of claims 20 to 23, wherein the subject has been diagnosed as having Alzheimer’s disease, frontotemporal dementia, Pick’s disease, corticobasal degeneration, progressive supranuclear palsyglobal glial tauopathy, argyrophilic grain disease, familial British dementia or familial Danish dementia.
25. The method of any one of claims 20 to 23, wherein the subject has been diagnosed as having a primary age-related tauopathy.
26. The method of claim 25, wherein the primary age-related tauopathy is selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy.
27. The method of any one of claims 20 to 26, wherein the compound or composition is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 2 weeks or more.
28. The method of any one of claims 20 to 26, wherein the compound or composition is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 12 weeks or more, 24 weeks or more, 48 weeks or more, 1 year or more, 2 years or more, or 5 years or more.
29. The method of any one of claims 20 to 26, wherein the compound or composition is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the compound or composition is no longer effective.
30. The method of any one of the previous claims, wherein the subject is a mammal.
31. The method of claim 30, wherein the mammalian subject is a human.
32. The method of any one of the previous claims, wherein the compound or composition is administered orally.
33. The method of any one of the previous claims, wherein the compound or composition is administered subcutaneously.
34. The method of any one of claims 20 to 31, wherein the compound or composition is administered topically, intranasally, systemically, intravenously, intraperitoneally, intradermally, intraocularly, ophthalmically, intrathecally, intracerebroventricularly, iontophoretically, transmucosally, intravitreally, or intramuscularly.
35. A method for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the compound of any one of claims 11-16, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof.
36. The method of claim 35, wherein the composition further comprises a pharmaceutically acceptable excipient.
37. The method of any one of claims 19 to 36 wherein the method further comprises administering at least one additional therapeutic agent.
38. Use of a composition in the preparation of a medicament for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition comprises the compound or any one of claims 1 to 16 or the composition of any one of claims 17 to 19.
39. The use of claim 36, wherein the composition comprises the compound of claim 16, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof.
40. The use of claims 38 or 39, wherein use of the composition reduces Tau species levels and / or reduces the toxicity associated with cellular Tau accumulation.
41. The use of claims 38 or 39, wherein use of the composition reduces cellular oxidative stress caused by cellular accumulation of Tau protein.
42. The use of any one of claims 38 to 41, wherein the subject has been diagnosed as having Alzheimer’s disease, Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, global glial tauopathy, argyrophilic grain disease, familial British dementia or familial Danish dementia.
43. The use of any one of claims 38 to 41, wherein the subject has been diagnosed as having a primary age-related tauopathy.
44. The use of claim 43, wherein the primary age-related tauopathy is selected from the group consisting of neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related Tau astrogliopathy.
45. The use of any one of claims 38 to 44, wherein the composition / medicament is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 2 weeks or more.
46. The use of any one of claims 38 to 44, wherein the composition / medicament is administered at least once per day, at least once every 2 days, at least once every 3 days, at least once every 4 days, at least once every 5 days, at least once every 6 days, or at least once every 7 days for 12 weeks or more, 24 weeks or more, 48 weeks or more, 1 year or more, 2 years or more, or 5 years or more.
47. The use of any one of claims 38 to 44, wherein the composition / medicament is administered beginning shortly after diagnosis and for the remainder of the subject’s life or until administration of the composition is no longer effective.
48. The use of any one of claims 38 to 47, wherein the subject is a mammal.
49. The use of claim 48, wherein the mammalian subject is a human.
50. The use of any one of claims 38 to 49, wherein the composition / medicament is formulated for oral administration.
51. The use of any one of claims 38 to 49, wherein the composition / medicament is formulated for subcutaneous administration.
52. The use of any one of claims 38 to 49, wherein the composition / medicament is formulated for administration, topically, intranasally, systemically, intravenously, intraperitoneally, intradermally, intraocularly, ophthalmically, intrathecally, intracerebroventricularly, intracerebroventricularly, iontophoretically, transmucosally, intravitreally, or intramuscularly.
53. Use of a composition in the preparation of a medicament for treating, preventing, ameliorating, inhibiting and / or delaying the onset of a tauopathy in a subject in need thereof, wherein the composition comprises the compound of any one of claims 11- 16.
54. The use of claim 53, wherein the composition further comprises a pharmaceutically acceptable excipient.
55. The use of any one of claims 38 to 54, wherein the composition further comprises at least one additional therapeutic agent.
Citation Information
Patent Citations
TAU-protein targeting compounds and associated methods of use
US20220315575A1
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7910741B2
TAU-protein targeting protacs and associated methods of use
WO2018102067A2
Compounds for TAU protein degradation
WO2019014429A1
